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SUMMARY
Background: in 1987, the first child with HIV-1 infection was identified in the paediatric wards
at King Edward VIII Hospital in Durban. This made paediatricians aware that the epidemic
had spread to the children of KwaZulu/Natal. Although information on transmission and
natural history was becoming available from developed countries, little was known about the
disease in developing countries. It was important to determine transmission rates and disease
patterns in the local population, in order to appropriately counsel women, and for management
of infected infants. In addition, with resources for laboratory diagnoses being limited in
developing countries, much emphasis had to be placed on clinical findings for identification of
infected children.
In 1989, a retrospective analysis was made of the HIV-infected children seen over a 2-year
period, between 1987 and 1989. Nine such children were identified and their clinical and
biochemical features were described. It was concluded that HIV infected children presented
with an identifiable pattern of signs, fairly similar to that described for children in industrialised
countries.
With these findings, a prospective study was undertaken, to determine the vertical transmission
rate, the factors affecting this rate, and natural history of vertically transmitted I-IIV-1 infection.
ix
KwaZulu/Natal, being at the epicentre of the epidemic in South Africa, was a natural site for
the study.
Patients and Methods: a trained research worker was placed in the antenatal clinic at King
Edward VIII Hospital for the specific purpose of educating, counselling, and testing of all
women attending the clinic. Women attending the clinic for the first time in the index
pregnancy were offered HIV testing if informed consent was obtained. Blood for HIV
serology was drawn at the same time as sampling for the obligatory syphilis serology. The
acceptance rate for sampling was > 95%. The majority of the women attending the clinic were
black, and first attendance was generally late, into the third trimester. The same research
worker was responsible for post-test counselling which was offered to all the women, not only
those who tested positive. This research worker was also responsible for obtaining maternal
consent for entering the newborn infant into the study.
All newborn infants were seen within 48 hours of birth. At this time they were examined,
growth parameters were recorded, and initial blood samples taken. These infants were then
followed-up at 1 month, 2 months, 3 months, then at 3-month intervals up to 18 months, then
at 6-month intervals. At each visit, a thorough clinical examination was performed, growth
measurements taken, and development assessed. Record was made of any interim illness and
visits to health centres, and of hospital admissions. Method of feeding was note& and details
on immunisation obtained from the child's immunisation card. The children received all the
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routine childhood immunisations according to the national regimen, based on WHO
recommendations.
Mothers were asked to bring the child to the follow up clinic for any problem, so that episodes
of illness would not be missed. The women were reimbursed for transport costs to encourage
follow up visits.
Calculation of transmission rate and classification of infection status were made according to
the recommendations of the Ghent workshop. Children were regarded as infected if they were
antibody positive at 18 months or had an HIV related death. They were classified as uninfectd
if the antibody test was negative at 9 months of age. Those infants who were lost to follow up
before the age of nine months whilst still antibody positive and those whose cause of death
could not be determined, were classified as indeterminate. The diagnosis of AIDS was based
on the WHO criteria.
Blood samples were taken at birth, at age one and three months, then at three month intervals
to 18 months; thereafter at six month intervals. Sera were tested for HIV1 antibodies by a
commercial enzyme-linked immunosorbent assay,ELISA. Samples that tested positive were
confirmed by two tests, a Roche Elisa and by an immunoflourescent assay (IFA). A sample
was regarded as being positive if both the second ELISA as well as the IFA or the Western
Blot tested positive.
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Results: between October 1990 and March 1993, 234 infants and their 229 mothers were
entered into the study. Those who did not attend a single follow up after birth were excluded
from the study. The final cohort comprised 181 infants, of whom 48 were classified as
infected ( including 17 deaths); 93 not infected, and 40 as indeterminate ( including 8 deaths).
Maternal Data: about 60% of the mothers were under 30 years of age and were multiparous;
18% tested positive for syphilis serology; 22.9% were anaemic during pregnancy, and 37%
were delivered by caesarean section. Most women lived in urban areas, and 16% chose to
bottle-feed exclusively.
Vertical Transmission Rate and Factors affecting this Rate: the median vertical transmission
rate was 34%, (95% confidence intervals, CI 26%-42%). This figure is similar to that found in
most parts of Africa, but much higher than those for Europe and USA. The maternal factors
found to be associated with an increased risk of transmission were vaginal deliveries and a low
haemoglobin level during pregnancy.
Breastfeeding, Transmission, and Outcome: breastfeeding was found to have an increased risk
of transmission, by 15 % (CI 1.8-31.8). On assessing growth and morbidity, it was noted that
breastfed infants were not protected against such common childhood infections as pneumonia
and diarrhoea, and that failure to thrive occurred with equal frequency in both those breastfed
as well as those receiving artificial feeds.
Newborn Data: when comparing newborn data between those infants who were subsequently
found to be infected with those who were uninfected, it was found that there were no major
differences between these groups with regard to growth parameters and neonatal
complications. However, those infants with rapidly progressive disease (those who died within
24 months), were noted to have lower mean birth weights and lengths, a higher frequency of
low birth weights, and tended to have more neonatal problems.
Clinical Manifestations: the first differences between the infected and the uninfected infants
generally manifested from about 3 months of age. HIV infected children were identifiable by
higher frequencies of thrush, lymphadenopathy, skin rash, and hepatosplenomegaly in the early
stages, and later on with a higher tendency to neurological and developmental abnormalities, as
well as of diarrhoea. Pneumonia was found with equal frequencies in both the infected and
uninfected children. The HIV infected child could be distinguished fairly early in life by the
combination of the manifestations described above.
Progression to AIDS: AIDS was diagnosed in 44% of all the infected children during the study
period. Ninety five percent of these children were identified by 12 months of life, showing a
rapid progression of the disease
Longitudinal Growth: when longitudinal growth parameters were analysed in this cohort, it
was found that HIV infected children were stunted from as early as 3 months of age, and
remained below the international standards into early childhood. Infected children were also
found to be malnourished (i.e. weight for age below international means), from an early age,
and this persisted throughout early childhood. Of note, the uninfected childrens' weights,
although comparable to international means initially, dropped after the first year of life.
However, both groups did not have significant wasting, when compared to international means.
Mortality: there were 25 known deaths during the study period. Of these, 17 were classified as
HIV-related, and 8 as indeterminate. The mean age at death was 10.1 months, with 83% of all
the HIV-related deaths occurring within the first year of life. The commonest diagnoses at the








The first persons with AIDS were described in 1981, in the United States. Since then, the
epidemic has risen to a global pandemic, with staggering figures of numbers of infected
persons. In 1983 the human immunodeficiency virus was established as the cause of the new
syndrome, and was noted to have a tropism for the CD4+ T lymphocyte (Amman 1983). The
first cases of AIDS in children were described in 1982, and the link between infected mothers
and their infants was established (CDC 1982). In 1985, an antibody assay was established for
laboratory diagnosis (Barre 1983). Reporting of AIDS cases in Africa began in 1983, with a
sharp increase from 1986 (Rosenberg 1992). In South Africa the first AIDS cases were
reported in 1982, occurring in white homosexual males (Epidemiological comments 1987).
The HIV pandemic has undergone four main phases in its evolution (Quinn 1996):
• emergence: the infection emerged from rural populations and spread to urban areas,
spreading silently among sexually active populations;
• dissemination: the virus spread rapidly to different regions of the world, through migration
and international travel. as well as due to enormous social disruption in Sub-Saharan Africa:
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• escalation: this occurred mainly in the eighties, as the infection spread into other high risk
populations and to the general population;
• stabilisation: this phase has become evident in some regions, such as North America and
western Europe, Uganda, Thailand, and whilst this may represent positive preventive
measures, it may also mean transition to an endemic status.
Spread of the epidemic has varied considerably between the developed and the developing
countries, depending on social, cultural and behavioural differences. Incidence rates have
been the highest in developing countries. At present 21 million of the total global number of
30.6 million adults and children living with HIV/AIDS are in sub-Saharan Africa (UNAIDS
1998). In South Africa, the prevalence of HIV-1 infection rose from 0.76% in 1990 to
16.01% in 1997. It has been estimated that, at the end of 1997, there were 3 million South
Africans infected with HIV (Dept of Health, unpublished surveillance data).
Tables for South Africa in Annexure 1.
1.2 Transmission of the virus
There are three chief modes of transmission of the virus:
• sexual transmission: which may be heterosexual, bisexual, or homosexual;
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• parenteral transmission: contaminated blood and blood products, contaminated needle and
syringes;
• vertical transmission from mother to infant: this may occur in- utero, during labour and
delivery, or postnatally through breastfeeding.
1.2 (a) Sexual transmission
Worldwide, heterosexual transmission is the chief mode of spread of the virus, accounting for
over 75% of all infections. In Africa, heterosexual transmission has always been the chief
mode of transmission, and, in some regions, 10-20% of 20-40 year old persons are infected
with the virus (Quinn 1996). Women are infected in equal numbers as men, leading to a major
problem of vertical transmission. In some regions of Africa, the seroprevalence rates at
antenatal clinics is as high as 30%.
1.2 (b) Vertical transmission
Vertical transmission of HIV-1 accounts for more than 90% of all infection in childhood.
The virus is transmitted from the infected mother to her infant, either antenatally, perinatally,
or postnatally. The exact contribution of each mode is not well established; however, most
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contribution during pregnancy, and some transmission occurring from breastfeeding.
Numerous studies have been done, which have established the transmission rates as well as
some of the factors which determine this rate (ECS 1992, Hira 1989, Lepage 1993). The rate
of transmission varies between different regions, from a low of 14% in the European
Collaborative Study, to a high of 52% in Africa. Most reports from Africa show a higher
transmission rate compared to countries from Europe and America. Whilst the exact reasons
for the variation in the transmission rate between regions is not certain, there are many possible
explanations for this. These include :
• breach of the placental barrier
• the stage of the HIV infection in the mother during pregnancy
• viral load in the mother during pregnancy
• maternal sexually transmitted diseases
• maternal nutrition and micro-nutrient deficiency during pregnancy
• anaemia during pregnancy
• advanced maternal age and increased parity
• inadequate facilities for labour and delivery
• breastfeeding
• maternal co-infections such as tuberculosis and malaria
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Several studies have shown that the mode of delivery may be significant in reducing
transmission; caesarean deliveries have been found to be protective against transmission (ECS
1992, Dunn 1994). Further reductions may occur if the caesarean section is carried out whilst
membranes are intact (Kuhn 1996). However, caesarean deliveries are not without morbidity
and complications may be increased in women who are HIV infected.
Sexually transmitted diseases are prevalent among women in Africa, and co-infection with
syphilis may lead to the breaching of the protective placental barrier, leading to an increased
risk of HIV infection. This increased risk, with active syphilis infection, has been reported in
some studies, but has not been found in others (Andiman 1991, Boyer 1994).
Poor nutrition in the mother as well as micro-nutrient deficiency may lead to an increased risk
of transmission. Studies have shown that transmission is increased if the mother is vitamin A
deficient (Semba 1994, Bridbord 1994, Mostad 1997). This may reflect general maternal poor
health as the risk factor, with the vitamin A acting as a surrogate marker. Similarly, it has
been shown that women who have lower haemoglobin levels have an increased risk of
transmission (St.Louis 1993). Again, the anaemia may be a surrogate marker for poor
maternal nutrition, or may be a marker for advanced stage of the HIV infection.
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Increased risk of transmission by breastfeeding is now widely accepted. A meta-analysis
established the increased risk as being between 7-20%, depending on the stage of the HIV
infection in the mother (Dunn 1992). In women with established infection at the time of
pregnancy, the risk is lower compared to women who become infected during pregnancy.
Much controversy surrounds the association between the duration of breastfeeding and the
risk. It is generally accepted that risk increases as the length of exposure increases, i.e. women
who feed for longer periods are more likely to transmit the virus than those who breastfeed for
shorter periods (Leroy 1998). The risk of late postnatal transmission varies from 5-32%
(Leroy 1998, Ehounou 1997)). Infants who are documented as being uninfected in the first
three months, but become seropositive thereafter, are deemed to have late postnatal
transmission. Acceptance of the role of breastfeeding as a potential source of transmission, led
to the WHO/UNICEF issuing a statement of recommendations, depending on the region in
which the woman lived (WHO 1992); in Annexure 11.
In 1996, the UNAIDS revised this policy and issued an interim statement which recognised
that women had the freedom of choice, no matter where they resided (UNAIDS 1996); in
Annexure 111.
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1.3 Viral Structure and Immunopathogenesis
(a) The virus
The human immunodeficiency virus is an RNA virus, belonging to the lentivirus family.
HIV virions contain a virus capsid, which consists of the major capsid proteins; the virion
envelope, and the matrix protein. There are two sub-types, HIV-1 and HIV-2. HIV-2 shares
40% genomic similarity with HIV-1, is geographically restricted to the west coast of Africa,
and causes a milder disease with slower progression (Bryant 1991).
HIV isolates show extensive genetic variability, with sequence variation even within patients.
During the course of infection, the distribution of virus variants changes, providing the basis
for the continous emergence of new virus variants. HIV isolates can differ in their tropism for
cells from different lineages. While the CD4 molecule is required for the entry of all HIV
variants, some variants are able to infect macrophages, and others show a preferential tropism
for T cells.
Extensive genetic analysis has revealed that HIV-1 isolates fall into two main groups,
designated M and 0 (Janssens 1997). Most isolates belong to the M group, which has at least
10 different sub-types (A-J). Subtype B is predominant in western Europe and USA; Africa
has several different subtypes, with subtypes B and C being predominant in South Africa
(Table 1.1).
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Table 1.1 The main viral subtypes in different regions









South Africa B, C
Thailand E
1.3 (b) Immunopathogenesis
Infection with the human immunodeficiency virus results in a profound immunosuppression, so
that the host is susceptible to various opportunistic infections and neoplasms. Effects of the
virus on the host may be particularly dramatic in children as many of the organ systems are still
developing.
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The principal target of the virus is the CD4+ T lymphocyte, due to the presence of the CD4
molecule on the surface of the cell. Infection with the HIV leads to a rapid cytopathic effect
on the CD4 cells. Some cells survive and maintain a low grade infectivity. The destruction of
the CD4+ cells leads to the profound immunosupression which is characteristic of AIDS. HIV
can also infect cells from the monocytic lineage, which express the CD4 molecule on their
surface. Thus HIV can infect monocytes and macrophages. Infection of these cells does not
lead to a decrease in their total numbers, nor are the cells destroyed. It is thought that they
function as a reservoir for the virus in various organs (Rosenberg 1992).
The precise mechanisms of HIV induced immunosupression are not well understood. HIV can
directly and indirectly infect CD4+ T cells, cause functional impairment of CD4+ T cells, as
well as of B cells and other antigen-presenting cells.
A period exists between infection and manifestation of disease, during which viral replication
occurs without any symptom manifestation (Perelson 1996). What causes activation from this
latent stage is under investigation. Numerous factors can induce HIV activation. These
include: mitogens, cytokines, and soluble factors such as interferons and TGF-11.
In 1993, the emerging group of small chemotactic-cytokines was designated "chemokines"
(Lindley 1993). In 1995, the first link between chemokines and the HIV virus was established,
with the discovery of the specific antiviral effect of regulated on activation of
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normal T-cell expressed and secreted (Rantes), macrophage inflammatory protein (MIP-1)
and MIP-1 (Cocchi 1995). These were found to be major components of the HIV-
suppressive activity produced by CD8 + T-lymphocytes. Following this, several chemokine
receptors, in particular. CXCR4 and CCR5 were shown to serve as co-receptors for HIV on
the cellular surface membrane (Deng 1996). The differential usage of such co-receptors, that
is critically dependent on the sequence of the V3 domain of the major viral envelope
glycoprotein, gp 120, is emerging as the physiological basis for the diversity among the HIV
isolates recovered at different stages of the disease. Moreover. a homozygous deletion within
the coding sequence of the CCR5 gene has been linked to resistance to HIV infection in some
individuals with multiple high risk exposure. The rapid progress in this field may ultimately
lead to the development of novel therapeutic approaches for AIDS.
Viral load: there has been a proliferation of information on viral load and disease progression
(McIntosh 1996). In children, of particular significance, is the relationship between viral load
in the mother and transmission of HIV, as well as viral load and disease progression in the
infant (Lambert 1997). Several studies have shown that a higher viral load in the mother is
associated with increased transmission, and that the risk is increased further if the mother has
high viral loads together with low CD+4 counts (Lambert 1997). In addition, infected children
with higher viral loads were found to progress more rapidly to AIDS and death, than infected
children with low viral loads (Pollack 1997). In antiretroviral therapy,
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viral loads are being used, together with CD+4 counts, for the monitoring of response to
treatment, and to monitor disease progression. It is important to remember that infants with
vertically acquired HIV infection have high viral loads in the first year (Palumbo 1995), with
levels falling off and reaching a steady state thereafter (Mcintosh 1996).
1.4 Diagnosis of HIV Infection
1.4 (a) Laboratory diagnosis
HIV infection is diagnosed by finding antibodies specific to the virus, or by detecting the
virus itself.
In adults, HIV antibodies are detected 6-8 weeks after the infection. HIV infected women
produce antibodies which cross the placental barrier to the fetus, so that all infants born to HIV
positive women will have anti-HIV IgG antibodies. The enzyme linked immunosorbent assay
(ELISA) is used for the detection of these antibodies. Confirmatory tests which are used
include: radioimmunoprecipitation (RIA), indirect immunoflourescent assay (IFA), and the
immunoblot (or western blot).
Diagnosis of infection comprises a positive ELISA plus a positive confirmatory assay, or two
positive ELISA. based on different methods, done on the same sample.
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The virus can be detected by the following tests: p24 -antigen. nucleic-acid based assays
(polymerase chain reaction, isothermic amplification), and virus culture.
1.4 (b) Diagnostic problems
In infants, maternal antibodies which cross the placenta can persist for up to 15 months of age;
therefore, diagnosis which depends on a positive HIV antibody test can be a problem as all the
infants would test positive. Diagnosis is further complicated by wide spread breastfeeding in
developing countries. The most suitable tests would be those that detect the virus itself.
However, the difficulty in developing countries is that these tests are extremely costly, and
therefore not generally available.
Since the anti HIV antibodies which cross the placenta are of the IgG class, detection of the
other classes, i.e. IgA and IgM would indicate infection in the infant. These assays are being
used and have been described in detail in the thesis on laboratory diagnosis by D. Moodley
(Moodley 1996).
As a result, in most of the developing countries, the ELISA is used together with clinical
criteria for the diagnosis of HIV infection and AIDS.
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1.5 Clinical Manifestations
The effects of vertically acquired HIV infection in the infant are widespread and multi-system.
Patterns of disease expression and progression differ among HIV infected children. It is
generally accepted that there are two major categories of infants: those who are rapid
progressors (about 25 %) and those who progress more slowly (Auger 1988, Duliege 1992).
Rapid progressors may have been infected in-utero or received a higher viral load, therefore
manifest earlier and progess more rapidly to symptomatic disease. AIDS, and death (Mayaux
1996).
Onset of manifestations may depend on the timing of the infection, i.e. in-utero vs
peri/postnatal. At birth, only a small proportion of infants of HIV positive women show signs
of infection, but most infants who are HIV- infected will manifest features of the disease by 6
months of age(Galli 1995). Age at onset of disease predicts length of survival.
The clinical manifestations of HIV disease have a wide spectrum. Some infants will present
with features of immunodeficiency, whilst others have non-specific signs. Non-specific
features include:
• hepato-splenomegaly





About 30-50% of children present with opportunistic infections at an early age (Scarlatti
1996). These include pneumocystis carinii infection, candidiasis, cytomegalovirus infection,
and tuberculosis. The survival rate in children with opportunistic infection is much worse.
Serious bacterial infections, lymphoid interstitial pneumonitis (LIP) and encephalopathy occur
frequently in HIV infected children. The prognosis is worse in those children with
encephalopathy than in those without this complication.
HIV-related malignancies, although uncommon in children, include non-Hodgkins lymphoma,
Kaposi's sarcoma, and MALT (Mucosal associated lymphoid tissue).
The natural history of vertically transmitted HIV-1 infection : at the time that this study was
conducted, little was known about the natural history of the infection in infants and children.
Subsequently, much information became available, chiefly from industrialised countries
(Johnson 1989, Scott 1989, Blanche 1990, ECS 1991). Information from Africa remains
minimal (Lepage 1990, Jackson 1992).
The natural history studies from various regions are discussed in Chapter 8.
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1.6 Classification of Disease
There are two widely used systems for the classification of HIV disease, the CDC (Centres for
Disease Classification, Atlanta, USA) and the WHO (World Health Organisation) classification
systems .
The WHO classification system for AIDS was established as the CDC criteria were considered
to be too sophisticated for most thirld world countries, which bear the brunt of the disease. For
reporting purposes, either one of the two systems is used .
The WHO classification system, which was modified in Geneva in 1989, includes the following:
Major criteria
• weight loss or failure to thrive
• chronic diarrhoea (> 1 month)
• prolonged fever (> 1 month )





• repeated common infections
• generalised pruritic dermatitis
• confirmed maternal HIV infection
For the diagnosis of AIDS, the infant must have at least two major in association with two
minor criteria.
The CDC classification system is used for the classification of disease, thus enabling uniformity
for the purposes of treatment and reporting (CDC 1994). Parts of the system can be used by
many regions; however, due to the lack of availability of CD4+ counts in most developing
countries, this part of the classification system would be impossible to utilise, (Table 1.2).
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* Category C and lymphoid interstitial pneumonitis (LIP) in Category B are reportable to
state and local health departments as AIDS (MMWR 36 : 15. 1987).
Children whose HIV infection status is not confirmed are classified by using the above
grid with a letter E (for perinatally exposed) placed before the appropriate classification
code (e.g., EN2).






The aim of the study was to describe the natural history of vertically transmitted HIV-1
infection, from birth to early childhood, in a cohort of infants followed prospectively from birth.
2.2 Specific objectives
• to determine the vertical transmission rate
• to determine maternal factors which might affect the vertical transmission rate
• to determine the effect of breastfeeding on the transmission rate and on the outcome in the
infant
• to determine the age at which maternal antibodies were lost in the infants
• to describe the neonatal characteristics and complications of the group, according to
infection status
• to determine onset of specific morbidity in the cohort
• to describe overall morbidity in the cohort
• to describe longitudinal growth in the cohort
• to determine the rate, onset and progression of AIDS in the infected infants





3.1 Study site and patient population
The study was conducted at King Edward VIII Hospital, situated in Durban, South Africa.
This is a large, urban hospital, where at least 99% of the patient population is black. The
hospital's obstetric unit handles approximately 16000 deliveries per annum.
Patients were recruited into the study between October 1990 and March 1993. A research
worker was trained in HIV education and counselling and was based at the hospital's antenatal
clinic. All women who were attending the clinic for the first time in the index pregnancy were
given education and counselling on HIV, as a group. If signed consent was obtained for HIV
testing, a sample of blood was taken at the time blood was drawn for syphilis serology, which
is obligatory at the study hospital. There was > 95% acceptance for testing. When results for
the test became available, personal counselling was offered to each woman. The possibility of
participating in the newborn and infant study was discussed only with the women who tested
HIV positive.
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When an HIV positive woman delivered a liveborn infant, permission was sought, by the same
research worker, to enter the infant into the study. Once written permission was obtained, the
infant was enrolled .
3.1 (a) Retrospective Study
The first children with vertically transmitted HIV-1 infection at King Edward VIII hospital
were recognised in late 1987 and early 1988. Based on the available data, we identified a few
children in our wards who fitted the given descriptions, tested them for HIV-1 antibody, and
collected their data retrospectively. Details on methods are included in the manuscript in
Chapter 4.
3.1 (b) Maternal Data
Information on the mother was obtained either from the newborn infants' charts, or













• ultrasound gestational assessment
• any complications
Labour and delivery:
• duration of labour
• method of delivery
• duration of ruptured membranes
• indications for assisted deliveries/ caesarean sections
22





• maternal medical complications
3.1 (c) Neonatal data
every neonate was examined within 48 hours of birth. A full clinical examination was
performed including general and systemic examination, growth parameters were measured, and
initial blood samples were taken. The following were recorded at this time:
• weight (at birth)
• gender
• apgar scores at 1 and 5 minutes






general examination including skin, eyes, umbilicus, genitalia,
lymphadenopathy, jaundice, anaemia
• systemic:respiratory /abdomen/neurological/cardiac/renal
• gestation, and whether small or appropriate for gestation
• sepsis
• surgical problems
Subsequent to discharge, the neonatal records were reviewed for any late complications,
particularly infections, jaundice, and neurological events. The duration of stay depended on
the presence of complications, and ranged from 12 hours to 30 days.
3.1 (d) Follow-up of infants
A follow-up clinic was established specifically for the follow-up of this cohort of infants and
comprised : paediatrician, 2 research scientists, and 2 research assistants (one of whom was the
same person based in antenatal clinic and therefore had the most contact with the mother).
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thereafter at 6 monthly intervals if available.
(ii) clinical assessments at each visit, the following were recorded:
• age
• weight, length, head circumference
• temperature
• skin rash
• lymhadenopathy: presence, sites, size
25
• eye, ear and throat examination




• history of diarrhoea/fever
• any interim illnesses/ visits to health care centres
• i mmunisation (from record card)
Growth parameters were plotted on NCHS (National Centre for Health Statistics) growth
charts.
Mothers were encouraged to bring the infants to the follow-up clinic for any complaint, so
that episodes of illness would not be missed, and to inform the team of any hospital
admissions. Where possible, the inpatient records for these admissions were obtained.
Transport costs were paid for all hospital visits, and the visits to the hospital were free, to
encourage follow-up. Defaulters were visited by one of the two research assistants, where
possible , to try and encourage revisits.
26
(iii) Immunisation:
all the infants were immunised according to the immunisation schedule developed for South
Africa, based on WHO recommendations. All the infants received BCG as well as oral polio
drops at birth, prior to discharge. Subsequent immunisation was done at community clinics. At
each scheduled hospital visit to the follow-up clinic, the immunisation records were checked
and information recorded. Mothers were encouraged to attend immunisation clinics if they had
lagged behind .
(iv) Blood testing:
• blood samples for HIV serostatus were taken at birth,1,3,6,9,12,15 18,24,36 months.
• at these times, additional samples were taken for serum globulin levels
• samples for full blood counts were taken at 3-month intervals
• during episodes of illness, additional tests were undertaken as necessary. These included:
cultures of blood, urine, stool and csf, full blood counts, viral serology, pus swabs, and
radiology.
3.1 (e). Classification of infection status:
The infants' infection status was classified using the recommendations of the workshop on
methodology held in Ghent, Belgium, in 1992. The reasons for this were:
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(i) maternal antibody may persist in the infant for up to 15 months of age; therefore, in
regions which use the antibody test alone, diagnosis is delayed
(ii) they allowed for classification of those infants who were lost to follow up early on in
the study, and for classifying early deaths
(iii) the same system could be used for the calculation of the vertical transmission rate.
Using this system, infants were classified as infected, uninfected, and indeterminate: Tables
3.1 to 3.4. Some modifications were made to allow for local differences in testing.
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Table 3.1
Ghent classification of children born to seropositive mothers according to their probable HIV
infection status (1992)
HIV-infected






HIV WB-serum-antibody-negative at 15 months
or
HIV WB-negative 9 months in a child lost to follow-up without AIDS
Or
HIV WB-negative 9 months in a child who died from probable non-HIV-related
cause
Indeterminate HIV infection status
Death before 15 months with indeterminate relation to HIV infection
or
Child died of probable not HIV-related cause while WB-positive or indeterminate
before 15 months or WB-negative < 9 months (when last seen)
or
Child lost to follow-up while WB-positive or indeterminate before 15 months or WB-
negative < 9 months (when last seen)
Or
Child with indeterminate WB and alive at 15 months
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Table 3.2
HIV-related signs and symptoms in children born to HIV-seropositive mothers used for the
Ghent classification of paediatric HIV infection.
Persistent diarrhoea (>. 15 days)
Oral candidiasis (beyond the neonatal period)
Generalized lymphadenopathy (enlarged lymph nodes in at least two independent anatomic
sites)
Failure to thrive (no weight gain for a period of 3 months or crossing two percentiles lines onm
the growth chart)
Chronic parotitis (> 1 month)
Herpes zoster infection (`shingles')
Recurrent pneumonia (two or more episodes)
Table 3.3
Definitions for children born to HIV-seropositive mothers who died before infection status




At least one HIV-related sign/symptom when last seen
and
Dying from severe infection or persistent diarrhoea beyond the first 4 weeks of life
Probable non-HIV-related death
No HIV-related sign/symptoms when last seen
and
Dying from cause other than severe infection or persistent diarrhoea after the first 4
weeks of life
Death with indeterminate relation to HIV infection
All deaths occurring within the first 4 weeks of life
Or
Beyond this period, all the deaths not classified above
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Table 3.4
Modified WHO clinical case definition for paediatric AIDS (1989)
Major signs
Weight loss or failure to thrive
Chronic diarrhoea (>1 month)
Prolonged fever (> 1 month)






Confirmed maternal HIV infection
Paediatric AIDS is suspected in a child presenting with a least two major signs and two
minor signs in the absence of known causes of immunosuppression .
3.2 Laboratory methods
HIV serology: the following methods were applied to all samples from mothers and infants,
for HIV serostatus determination. All samples were initially tested using a commercial
enzyme-linked immunosorbent assay, ELISA ( Abbot Laboratories, N. Chigaco, IL). Those
samples which tested positive were then confirmed with two tests, a Roche ELISA (Cobus
Core, Besel, Switzerland), and an immunofluorescent assay, IFA, (Virion, Cham,
Switzerland). Samples which tested negative with the IFA, were then tested by a Western
Blot assay(diagnostic biotechnology). Samples were regarded as positive if the second
3 1
ELISA was positive, or if either the 'FA or Western Blot was positive. These methods were
applied to both the maternal and infants' blood samples.
More details on laboratory methods are described in the various chapters, according to the
investigations used therein.
3.3 Statistical methods
Details on statistical methods used are provided in each chapter. However, some salient
details are highlighted below:
3.3 (a) Calculation of vertical transmission rate:
the recommendations of the Ghent methodology workshop were used for this. Three
different transmission rates are calculated, an upper, a lower, and an intermediate estimate .
These calculations take into account those infants lost to follow-up, whose infection status
was indeterminate:
the upper estimate: assumes that all indeterminate infants were infected;
the lower estimate: assumes that all indeterminate infants were uninfected; and
the median estimate: assumes that all indeterminate infants do not contribute to the
calculation of the vertical transmission rate.
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The intermediate estimate is used for reporting purposes.
The method used for the calculation:
upper estimate: TR = (n+) + (n?) / N
lower estimate: TR= n+ /N
intermediate estimate: TR = (n+) / (n+) + (n-)
where TR= transmission rate; N= total number in cohort;
n+ = positives; n- = negatives; n? = indeterminates
The 95% confidence intervals were calculated thus:
95% CI = TR ± 1.96 x -\/ TR x (1-TR)
D
where TR = transmission rate, and D is the denominator used in calculation.
3.3 (b) Factors affecting vertical transmission rate:
maternal risk factors which could impact on the vertical transmission rate were analysed in a
univariate analysis; the results are presented as relative risks and 95% confidence intervals.
These were then included in a multivariate analysis to determine whether the effect of those
found significant would remain; again results are presented as relative risks and 95%
confidence intervals.
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3.3 (c) Effect of breastfeeding on outcome of infants:
described in chapter 7.
3.3(d) Neonatal characteristics and outcome:
described in chapter 8.
3.3(e) Morbidity, natural history, and progression to AIDS:
described in chapter 9.
3.3(f) Growth:
described in the chapter 10.
3.3(g) Mortality:
described in chapter 11.
3.4 Ethical Approval
This study was approved by the Ethics committee of the Faculty of Medicine, University of
Natal.
Permission for conducting the study was obtained from the medical superintendent of King





SOME EARLY OBSERVATIONS ON HIV INFECTION IN CHILDREN
4.1 Summary
Nine black children aged between 3 months and 30 months of age, with human
immunodeficiency virus I infection are described to draw the attention of health
professionals in Southern Africa to special clinical characteristics useful for recognising this
problem, which has many shared features with common diseases of infancy and childhood in
the Third World. The main presenting complaints were chronic cough and persistent diarrhoea
and vomiting. These children frequently had diarrhoea (8 of 9 patients), mucocutaneous
candidiasis (8), pneumonia (7), hepatosplenomegaly (9), significant lymphadenopathy (5) and
wasting, (5). All were infected by common bacteria, such as Gram-negative organisms,
Mycobacterium tuberculosis and Carnpylobacter jejuni, or by opportunistic infections such as
Candida or cytomegalovirus (CMV), or by both bacterial and opportunistic organisms. A
raised total serum globulin level, anaemia, lymphopenia and a cerebrospinal fluid (CSF)
pleocytosis were frequent findings. Incomplete data on parental HIV status suggest perinatal
transmission. Three of the children were HIV-antigen positive. The diagnosis of full-blown
acquired immunodeficiency syndrome (AIDS), using the stringent Centers for Disease Control
JS
criteria, is difficult in our situation because of limited diagnostic resources; however,
using these criteria, and the clinical case definition for AIDS recommended by World
Health Organisation, it is thought that probably 4 of these children could be considered
as having AIDS.
Any child with an elevated serum globulin level, CMV infection, an unexplained
abnormal CSF, an unusual or unresponsive form of tuberculosis, long-standing
symptoms of common childhood illnesses and found to have diarrhoea, pneumonia,
mucocutaneous candidiasis, hepatosplenomegaly, lymphadenopathy and wasting should
be evaluated for the presence of HIV infection.
4.2 Introduction
There are increasing numbers of children with human immunodeficiency virus type I
(HIV-I) infection and the acquired immunodeficiency syndrome (AIDS) throughout
much of the world and in South Africa (Update:AIDS 1988, Aids update 1988). By
October 1989, there were 12 reported cases of AIDS in South African children (AIDS
advisory group 1989), and this figure is expected to increase annually in geometric
leaps.
Since early 1988, an increasing number of children with HIV infection have been
diagnosed in the paediatric wards at King Edward VIII Hospital Durban. While
information is steadily becoming available about clinical features, management,
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mortality, morbidity and outcome of HIV infection and AIDS in children in Western
countries (Falloon 1989, AIDS:update 1989, Connor 1987) little is known about these
aspects in children in Africa. Among adults in Africa, AIDS has been shown to be different
from the disease in the West (Schoub 1986).
There is considerable overlap between the features of HIV infection/AIDS described among
children in rich industrialised countries and the common diseases occurring among children
in the Third World, e.g. protracted diarrhoea, chronic chest infections, malnutrition and
tuberculosis. It is therefore important for clinicians to be able to distinguish children with
these common conditions from those with HIV infection/AIDS, for appropriate prophylaxis,
close observation and monitoring, as well as prompt treatment of intercurrent infections.
4.3 Patients and Methods
This retrospective study was carried out at King Edward VIII Hospital, Durban. Data were
collected on all those children found to have a positive WV-antibody test between April
1988 and July 1989. Only children with positive results on both the enzyme-linked
immunosorbent assay (ELISA) and Western blot were included. Initial WV-antibody
testing had been done if the mother was known to be HIV-positive or if the
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attending clinician suspected HIV infection/AIDS. One child was tested three times - at
1 month and 12 months after initial test.
These children had detailed clinical assessments and varying degrees of investigations
were performed. The investigations included HIV-antibody testing (by ELISA and
Western blot); HIV antigen test (by ELISA); a full blood count and a differential count;
cultures of blood, urine, stool and cerebrospinal fluid (CSF): examination of the CSF by
microscopic and chemical methods; liver function tests; the TORCH screen; chest
radiography; and Mantoux tests. Lymph node and liver biopsies and computed
tomography (CT) had been done only where indicated. Cytomegalovirus (CMV)
infection was diagnosed on the basis of a specific IgM antibody in serum, by liver
biopsy, and by microscopic examination of the urine. In order to define lymphopenia,
values for age-matched normal black children were used (Kiepiela 1989) .
Parents' HIV status was tested where one or both parents were available and consent
was obtained. The patients were categorised according to the classification system for
HIV infection in children under 13 years of age recommended by the Centers for Disease
Control (CDC) in Atlanta, Georgia, USA (Classification 1987). The total serum
globulin levels were compared with those in age-matched patients with the following
diagnosis: CMV infection without HIV infection (5 patients) ; tuberculosis (10), protein-
energy malnutrition (20), and diarrhoeal illness requiring admission to hospital (20).
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4.4 Results
During the study period of 15 months, 9 black children were identified as being HIV-
antibody positive.
Table 4.1 shows their age at time of diagnosis, gender, presenting complaints and
duration, place of residence, the CDC classification for HIV exposure, and outcome.
Patient 3 was tested 3 times, and the positivity of the antibody test had increased with
each subsequent testing. The mean age of these children was 13,2 months (range 3-30
months). There were 5 boys, and 7 patients came from urban areas. their main
presenting complaints were chronic cough (6 of 9 patients), diarrhoea and vomiting (5)
and loss of weight (2). Four children died (patients 1, 5, 7, and 9), their duration of stay
in hospital varying from 1 day (patient 9) to 9 months (patient 1). Four children (patients
1, 3, 4 and 8) were aged > 15 months, the cut-off age used for presence of maternal
antibodies.
The main clinical features of these patients are shown in Table 4.2. Six children were
below the 3rd percentile for weight (National Center for Health Statistics (NCHS)
standards). The patients nearly always has diarrhoea (8 of 9 cases), candidiasis (8),
pneumonia (7), hepatosplenomegaly (7) and often had significant lymphadenopathy (5)
and wasting (6). The significant laboratory results and radiographic findings are shown
in Table 4.3. All the children had bacterial and/or opportunistic infections. Bacterial
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infection was due to common organisms such as Gram-negative Escherichia coli,
Mycobacterium tuberculosis, and Campylobacter jejuni. One child (patient 1) had
massive tuberculous lymphadenopathy with no response to conventional antituberculosis
drug therapy and died after 9 months' treatment in hospital. The most common
opportunistic infection was candidia (8 of 9 patients) followed by CMV (5). CMV was
diagnosed by a positive IgM (in 5 of 5 patients tested) and in 1 child (patient 7) CMV
was also found in the urine and on liver biopsy. The CSF was found to be abnormal in 6
of the 9 children, the main abnormality being a pleocytosis; the total protein was
elevated in 1 child.
Anaemia was present in 8 children, 6 had lymphopenia, while none had
thrombocytopenia. The total serum globulin level was markedly elevated in all those
tested, with a mean level of 56,8 g/1 (range 37 - 78 g/1). In contrast, the means for the
other conditions investigated were: CMV infection - 29 g/l (range 25 - 37 g/1), gastro-
enteritis - 27,4 g/l (range 17 - 49 gip, protein energy malnutrition - 26,2 g/1 (range 8 - 38
g/l) and tuberculosis - 35,7 g/1 (range 23 - 48 g/l).
Immune function testing had been done on only 3 children (patients 1, 2 and 4). The
results of these showed a depressed CD4:CD8 ratio of 0,07, 0,09 and 0,20, respectively
(Kiepiela 1989). The T-cell function (phytohaemagglutin transformation) was impaired
in patient 4, normal in patient 2, and was unsuitable for comment in patient 1.
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CT was performed on 1 patient, No. 7, and this showed generalised cerebral atrophy .
All the children's sera was tested for the presence of HIV antigen. This is not yet a sensitive
test in our laboratory (I.M. Windsor - unpublished observation). Three of the 9 were found to
be positive (patients 2 , 6, 9) and they were all < 15 months of age.
The mothers of 2 children were known to be HIV-antibody positive at the time the patients
were admitted to hospital. Three sets of both parents were available for HIV-antibody testing;
of these 2 sets of both parents were HIV-positive, while in 1 set only the mother was positive.
The social and sexual histories were available for the parents of 2 children. One set of parents
were both teenagers, were still at school and each of them admitted to having had several
sexual partners. In the other set of parents, the father had 2 wives and 6 children, 2 from the
mother of the patient and 4 from the other wife. He himself was antibody negative. The
mother refused to give a history regarding her sexual contacts.
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1 24 M Urban
2 13 F Urban




4 30 F Rural
5 8 M Urban
6 3 M Urban
7 5 M Rural
8 16 F Urban
9 5 M Urban
Cough (2) PII
Swelling in neck (1) D I
Failure to thrive, cough, P I
vomiting (2) D I
Diarrhoea : recurrent (5)
Cough, fever, P H
vomiting (1) D I
Persistent pneumonia (6)
Cough, P II
loss of weight, D I
fever (2)
Recurrent diarrhoea ( 3) P 0
Cough, P II
fever (1) D I
Cough, P II
failure to thrive, B
unresolving pneumonia (2)
Recurrent diarrhoea ( 7) P H
D 11
Cough, P H














Presenting complaints classification Outcome and
and duration (months.) for HIV duration of
infection stay (mo.)
* Refers to duration of hospital stay from admission to death
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1 + Generalised 9,3 (< 3rd)
2 + Generalised + + - - 7,1 (< 3rd)
3 + Axillary + + + + 6,4 (< 3rd)
4 - - - - + + 12,3 (25th)
5 + Generalised + + + + 2,7 (< 3rd)
6 + - + + + + 5,5 (50th)
7 + Generalised + + + + 3,7 (< 3rd)
8 + - + + + + 7,9 (3rd)
9 + - - - 8,0 (75th)
* (NCHS centile)
+ = present; - = absent
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With the expected increase in the number of infants and children with HIV antibodies, HIV
infection and AIDS, especially among blacks, there is an urgent need for health professionals
caring for children to become aware of those features of this condition which might apply in
the local situation. This preliminary account of a small sample of 9 hospitalised black infants
and children with HIV infection attempts to do this; it draws attention to a few characteristics
that are useful for recognising this syndrome, which has many features shared by the common
diseases of infancy and childhood in poor countries.
The presenting symptoms were indicative of respiratory and gastro-intestinal problems; since
these two conditions are the most frequent causes of morbidity and mortality among children in
the Third World, these symptoms did not in themselves signal the likelihood of a background
HIV infection. The protracted duration of the complaints may have given a hint about the
seriousness of the underlying process; However, this is a highly subjective factor in our
environment and was therefore of doubtful value. The patients almost always had diarrhoea,
pneumonia, mucocutaneous candidiasis and enlargement of the liver and spleen; they often had
significant lymphadenopathy and wasting. It is this combination of clinical features, rather than
any individual problem, which should alert the health professional to the probability of HIV
infection. Diarrhoeal disease, respiratory tract infections and protein-energy malnutrition,
taken separately, may occasionally each show evidence of all these above findings, but very
often do not
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Stronger support for the diagnosis of HIV infection is provided by the additional
detection of an elevated serum globulin level, CMV infection, CSF pleocytosis and
unusual manifestations of tuberculosis. Such an assembly of clinical problems increases
the likelihood of HIV infection even further. Overt CMV infection, especially the intra-
uterine type, is exceedingly uncommon among black children in our experience. The
extent of serum globulin elevation in AIDS among the children reported here was far in
excess of that seen in common chronic diseases, such as tuberculosis, malnutrition and
diarrhoea. It was also higher than that in CMV infection without concomitant HIV
infection. The presence of raised globulins has been noted in other studies of paediatric
HIV infection and AIDS (Oleske 1983, Mok 1989, Pahw 1986), and may accordingly
be the single most important simple test for supporting this diagnosis.
In Western countries, the main clinical features in children with HIV infection are failure
to thrive, recurrent fever, thrush, diarrhoea and lymphadenopathy (Falloon 1989, Connor
1987). Our patients had nearly all these features and, in addition, hepatosplenomegaly
was a common finding. Pulmonary disease accounts for most of the morbidity and
mortality associated with HIV infection in American children, with Pneumocystis cannii
being the most common opportunistic infection (Connor 1987). Lymphoid interstitial
pneumonia (LIP) also occurs frequently (Connor 1987).
Disseminated CMV infection is the second most frequent opportunistic infection,
followed by Candida (Schoub 1986). The cause of pneumonia in our patients remains
unknown.
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Although we did not look for P. carinii or LIP, there was a high incidence of persistent or
recurrent pneumonia; in 1 child the chest radiograph was suggestive of LIP (Rubinstein 1986).
As in children from industrialised countries, anaemia was a consistent feature (Oleske 1983) .
Thrombocytopenia, which is frequently found (Saulsbury 1986, Shannon 1985), was not seen
in any of our patients whereas lymphopenia, which is not described as a common finding in
children in the USA (Pahw 1986), was frequently found in our patients.
Central nervous system involvement includes encephalopathy, developmental delay,
microcephaly, cerebral atrophy and CSF abnormality (Connor 1987, Epstein 1986, Epstein
1985). Our results show that CSF abnormality occurred frequently among our patients. One
child had CT and this showed generalised atrophy. The children were nor adequately assessed
for developmental delay.
Cardiomyopathy, arteriopathy and the nephrotic syndrome have been described in American
children (Connor 1987). None of our patients had cardiac or renal involvement. Kaposi's
sarcoma was not found in any child and, in all reports to date, is said to be rare (Falloon 1989).
The overall mortality given for American children with AIDS is 50-65% (Falloon 1989,
Connor 1987). The mortality in our series was 45%. The causes of death were disseminated,
unresponsive tuberculosis and extensive pneumonia .
Although 5 of our 9 patients were < 15 months of age (which is the cut-off age used for the
persistence of maternal antibodies), 3 of them were antigen-positive, and the other 2 had other
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criteria consistent with making the diagnosis of HIV infection as described by the CDC
(Classification 1987). Diagnosis of AIDS, as proposed by the CDC (Revision 1987), is
difficult in our situation because of limited diagnostic resources and the stringent criteria.
However, on the basis, possibly patients 1 and 8 would match the required criteria. Using
WHO criteria (WHO 1986) for the clinical case definition of AIDS where diagnostic resources
are limited, then patients 2 and 4 would probably also fulfil the criteria.
Our data are incomplete in certain important respects, such as immune function testing,
parental HIV status, history regarding risk factors and possible modes of infection. However,
we felt it important to share our limited clinical experience at this stage with other clinicians
caring for children, in order to alert them to the features of this condition in South African
children. A prospective study is being planned in order to delineate some of the unanswered
questions referred to above, and to compare local experience of paediatric AIDS with that
reported from the West.
Addendum
By the end of August 1990, a further 21 children were diagnosed as being HIV-positive; 18 of
them were regarded as having symptomatic HIV infection and would fall into the PII category
of the CDC classification. Of these 18,5 children fulfil the WHO criteria for the diagnosis of








Infants were enrolled into the study between October 1990 and April 1993.
During this period, 234 infants and their 229 mothers were entered into the study. Fifty three
infants were not brought back for a single follow-up visit after discharge from the neonatal unit,
could not be traced by the research workers, and were excluded from the study. Unrest and
political violence in the province of Kwa/Zulu Natal during the study period led to large
numbers of people moving from one area to another, so that the original address changed; in
addition, women sometimes returned to remote rural areas after delivery and therefore could
not be reached. This group of patients was compared to the rest of the cohort with regard to
maternal, labour and delivery data, and was found to be comparable to the rest of the cohort,
and susequently excluded from all analyses.





The infected _group included 17 deaths, and the indeterminate group included 8 deaths from
unknown aetiology.
There were 5 sets of twins in the cohort. There was concordance in three sets, 1 set being
infected and two uninfected; discordance occurred in one set, where twin 1 had an HIV
related death and twin 2 remained uninfected; in the last pair, twin 1 was stillborn and twin













Some of the maternal characteristics assessed are shown in Table 5.1
The mean age of the mothers was 24 years, (range 16 to 40 years). Forty four of the women,
33%, were primiparous. A positive syphilis serology was found in 23 (18%) of the women.
Forty four women (37%) were delivered by caesarean section. of which 77% were emergency
caesarean deliveries (this high rate is due to the study hospital being a tertiary referral centre,
and black women having a greater tendency to cephalo-pelvic disproportion). Of those who
delivered vaginally, 39% had an episiotomy or tear. Only 17 (13%) of the deliveries occurred
before 36 weeks gestation. Twenty one of the mothers (16%) did not breastfeed at all.
At the time of delivery, only 5 women were symptomatic for HIV infection, and none was
given the diagnosis of AIDS. There were two maternal deaths in the puerperium, both non-
HIV related (one from cardiac disease and the other from peurperil sepsis).
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Table 5.1 Characteristics of the maternal population
Characteristic Number (%)
age ^ 30 years 54 40.3
< 30 years 80
parity p 0 44 33.8
p 1+ 86
syphilis serology positive 23 18.1
negative 104
haemoglobin level  10 g/I 25 27 . 9
>10 g/1 84
delivery caesarean 44 36.7
vaginal 76













DETERMINANTS OF MOTHER-TO-CHILD TRANSMISSION OF HIV-1
INFECTION IN A COHORT FROM DURBAN, SOUTH AFRICA
6.1 Summary
Objectives: To determine the vertical transmission rate of HIV-1 infection and to assess
the influence of maternal risk factors on transmission in infants born to HIV-1 infected
black women in Durban.
Design: A prospective, hospital-based cohort study conducted at King Edward VIII
hospital, Durban. HIV-1 seropositive women were enrolled into the study and their infants
followed up at regular intervals from birth to early childhood. Classification of infection
status of the children and computation of transmission rate were done according to the
recommendations of the workshop held in Ghent, Belgium(1992).
Results: The final cohort of 181 infants were classified as: 48 infected, 93 not infected
and 40 indeterminate. Clearance of maternal antibodies was achieved by 12 months of age
in virtually all infants who became seronegative. The intermediate transmission rate was
34% (95% C I 26%-42%). Deliveries by caesarean section were found to have
significantly lower transmission, R.R.=0.46 (95%C.I. 0.23-0.91). Women with lower
hemoglobin levels during pregnancy (less than 10 g/dl) had an increased risk of
transmission, R.R.-1.99 (95%C.I. 1.18-3.34). Advanced maternal age, multiparity, positive
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syphilis serology, duration of ruptured membranes, preterm delivery and breastfeeding*
were not associated with an increased risk of transmission.
Conclusions: This study, the first from South Africa, has confirmed that the rate of vertical
transmission of HIV-1 is as high as that reported from most African cohorts. Caesarean
sections were protective against transmission, while low hemoglobin levels were associated
with an increased risk of transmission. Twelve months could be used as the cut-off age for
the diagnosis of vertical infection using antibody tests.
*N.B. In this observation, we had compared ever breastfed versus never breastfed. In the
next chapter, we discussed breastfeeding in more detail, comparing exclusive , mixed, and
formula fed infants.
6.2 Introduction
The Human Immunodeficiency Virus 1(HIV-1) epidemic which began later in South Africa
than in the rest of the continent, is spreading rapidly in the country, especially among young
black women of child-bearing age (Abdool Karim 1992, Kustner 1995). According to
national surveys the prevalence rates at antenatal clinics in the country range from a low of
1.16% in Western Cape to a high of 14.35% in Kwa7u1u/Natal (Kustner 1995). Since
more than 90% of HIV-1 infection in childhood occurs by vertical transmission, an
increasing number of infected women will lead to large numbers of infected children. The
magnitude of the problem depends on the vertical transmission rate in the local population
and the factors influencing this rate.
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The vertical transmission rate varies considerably among regions, with low rates reported
from Europe(14%) to much higher rates from central and southern Africa (up to 45%)
(ECS 1992, Lepage 1993, Hira 1989, Ryder 1989, Lallemant 1994). Why these differences
exist is not yet fully understood and is the focus of many studies. One possible explanation
is differences in methodology; this can be addressed by the use of standardized methods as
recommended by the workshop held in Ghent in 1992 (Dabis 1992, The Working Group
1995).
It is now well accepted that infection of the infant can occur in utero, during labor and
delivery, and in the postnatal period (Mofenson 1994), although the proportion of each is
not known. Some of the risk factors that have been assessed in various studies include: low
CD4 counts during pregnancy, presence of symptoms in the mother, maternal p24
antigenemia, disruption of the placenta, mode of delivery, and feeding practice (ECS 1992,
Hira 1989, Lallemant 1994,Borkowsky 1992, Gabiano 1992, Dunn 1992). The European
Collaborative Study found that caesarean sections decreased the risk of transmission (ECS
1994) and the first report of the same finding for an African cohort came from an interim
analysis of the study cohort (Moodley 1994). A meta-analysis done on feeding methods
found that breastfeeding could increase the risk of infection by 14% (Dunn 1992) in those
mothers with established infection. This is of particular importance in developing countries
where breastfeeding is widespread.
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In order to counsel and care for HIV infected expectant mothers appropriately, it is
necessary to establish the vertical transmission rate in the local population, and to assess the
effects of a variety of risk factors. Thus a study was undertaken in Durban, in the province
of Natal Kwazulu, which is at the epicentre of the HIV-1 epidemic in South Africa (Kustner
1995).
6.3 Patients and Methods
This report derives from a prospective, hospital based, cohort study, on the natural history
of vertically transmitted HIV-1 infection. The study was conducted at King Edward WIT
Hospital, a large urban hospital in the city of Durban. At least 95% of the patients attending
the hospital are black.
Approval for the study was given by the Ethics Committee of the University of
Natal's Medical Faculty and the medical superintendent of the hospital.
6.3.1 Patient population
All the details on patient population have been provided in Chapter 3.
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Data on maternal aize and parity, obstetric history, antenatal care and circumstances around
labor and delivery, as well as results of hemoglobin and syphilis serology were obtained
from the newborn infants' records at delivery as well as retrospectively from the obstetric
charts. Gestation was determined from ultrasonography done on every patient at the first
antenatal visit.
The decision to perform caesarean section on the women was in no way influenced by the
HIV-1 serology result. In addition, AZT was not being used on pregnant women at this
hospital during the study period.
6.3.2 Laboratory Methods
Refer to Chapter 3 .
6.3.3 Classification of infection and calculation of transmission rate
The recommendations of the Ghent Workshop on methodology were used for the
classification of childrens' HIV-1 infection status and for the calculation of mother to child
infection rates (Dabis 1992). Briefly, children were classified as positive if: they were
antibody positive at 15 months, or if they fulfilled WHO criteria for AIDS, or if they had an
HIV-1 related death. Children who became antibody negative after age nine months, as
well as those who died of a non HIV-1 related illness, were classified as not infected; and
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those infants who were lost to follow-up or died of an unknown cause before the age of 15
months, while still antibody positive, were classified as indeterminate.
6.3.4 Statistical methods
The data for the univariate analysis are presented using relative risks (R.R.) and 95%
confidence intervals. Logistic regression was used to examine the simultaneous effects of
several variables which included maternal age, parity, syphilis serology, hemoglobin,
gestation, method of delivery, and feeding method. Twins were excluded from both the
above analyses. The rate of loss of maternal antibody was calculated using life table
methods.
6.4 Results
Between October 1990 and April 1993, 234 Black infants and their 229 mothers were
entered into the study. All the children in the study were born at least 18 months prior to
the time of analysis. Follow- up of the cohort was ongoing at the time of this analysis.
6.4.1 Classification and transmission rate
Fifty-three of the patients did not attend a single follow up visit after birth and could not be
traced by field workers. Unrest and political violence in the province led to large numbers
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of people moving from one area to another; in addition, patients sometimes returned to
remote rural areas immediately after delivery and were lost to follow up. This group was
no different from the rest of the cohort with regard to the risk factors analyzed and was
excluded from subsequent analyses. The remaining 181 patients were classified as
follows: 48 infected (including 17 deaths), 93 not infected, and 40 indeterminate (this
includes 8 deaths from unknown causes and 32 losses to follow up between one and nine
months of age, while still antibody positive). There were 24 known deaths at the time of
analysis, of which 16 were HIV related. Of the 5 sets of twins in the cohort, there was
concordance in 3 sets of twins, one set being infected and two sets not infected;
discordance occurred in one set, where twin one had an HIV-1 related death and twin two
has remained uninfected. In the last pair, twin 1 was stillborn and twin two had an HIV-
related death.
Using the direct method for the calculation of the vertical transmission rate (Dabis 1992),
the following results were obtained: the median estimate, which assumes that
indeterminate children do not contribute to the vertical transmission rate, was 34% (95%
CI 26%-42%). The upper estimate, which assumes that all indeterminate children are
infected, was 48% (95% CI 40%-60%); and the lower estimate, which assumes that all
indeterminates are not infected, was 26.5 % (95% CI 20%-33 %).
59
6.4.2 Maternal Data
The mean age of the mothers was 24 years (range 16-40 years); and 43(32%) of the
women were primiparous; 23(18%) had a positive syphilis serology; 44(35%) were
delivered by caesarean section, of which 77% were emergencies. Of those delivered
vaginally, 39% had an episiotomy or tear. Only 17(13%) of deliveries occurred before 36
weeks' gestation. Twenty-one (16%) of the mothers did not breast feed at all (duration of
breastfeeding ranged from one week to 30 months).
At the time of delivery, only 5 mothers were symptomatic for HIV infection. There were
two maternal deaths in the puerperium, both due to non HIV related causes.
6.4.3 Analysis of risk factors
The univariate analysis of various risk factors is shown in (Table 6.1). The significant
findings were: deliveries by caesarean section had a lower risk of transmission than
vaginal deliveries, relative risk:0.46 (C.I. 0.23 to 0.91); women with a low hemoglobin
during pregnancy were at increased risk of transmission, R.R.---1.99 (C.I. 1.18 to 3.34). No
significant risk of transmission was noted for the following factors: advanced maternal age,
multiparity, positive syphilis serology during pregnancy, delivery before 36 weeks'
gestation, duration of ruptured membranes, and breastfeeding (Refer previous
explanation). When duration of membrane rupture was analysed using 4 hour and 6 hour,
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Maternal age ^30 years 17 34 1.03 0 62-1 69
< 30 years 26 54
Multiparous 29 57 1.04 0.61-1.75
Primaparous 14 29
Syphilis serology: positive 6 17 0.73 0.35-1.53
negative 37 67
Hemoglobin  10g/d1 13 12 1.99 1.18-3.34
>10g/d1 22 62
Gestation -_36 weeks 6 11 1.08 .0.54-2.16
>36 weeks 38 77
Deliveries caesarean 8 36 0.46 0.23-0.91
vaginal 30 46
Ruptured >17 4 11 0.86 0.35-2.09
hours 29 64
Ever breastfed 38 72 1.44 0.64-3.22*
Never breastfed 5 16
C.I.=confidence intervals
# R.R. = relative risk.
Numbers do not always add up to 44 infected and 88 not infected because of
missing data. Twins are excluded (4 infected and 5 not infected).
* Refer explanation in Summary (6.1).
61
instead of 12 hour cutoff times, no association was found with risk of transmission.
In a more detailed examination of the method of delivery, no significant difference was
found between the 33 emergency and 11 elective caesarean deliveries; 7/33 infants delivered
by emergency caesarean and 1/11 delivered by elective caesarean were infected. Similarly,
no increased risk of infection was noted in those infants born vaginally with intact perineum
(17/46) vs those delivered vaginally with episiotomy or laceration (13/30).
In the multivariate analysis, the decreased risk of transmission for deliveries by caesarean
section as well as the increased risk for low hemoglobin values, remained significant.
When the analysis was repeated including the children whose status was indeterminate with
the infected group or the uninfected group, the effects of low hemoglobin and caesarean
delivery were similar (Table 6.2).
6.4.4 Clearance of maternal antibodies
Figure 6 1 shows the rate of loss of maternal antibodies according to age. At birth, 100%
were antibody positive, with 98% remaining positive at 6 months. Thereafter, the rates
changed rapidly with 63.9% positive at 9 months and 29.2% positive at 12 months. A
plateau effect was seen from 12 months. For those infants becoming antibody negative,
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Table 6.2. Results of multivariate analysis
Variable Relative Risk (95% C.I.)
group A group B group C
Low hemoglobin 3.20 (1.23-8.28) 2.74 (1.05-7.13) 2.88 (1.09-7.57)
Caesarean delivery 0.37 (0.14-0.95) 0.32 (0.12-0.84) 0.33 (0.13-0.88)
group A= infected + indeterminate vs not infected
group B = infected vs not infected + indeterminate
group C = infected vs not infected
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Figure 6.1 Clearance of Maternal Antibodies.
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clearance was achieved by age 12 months in almost all (92/93). At the time of analysis no
child who became antibody negative had subsequently seroreverted (with follow up
ranging from 21 to 48 months).
6.5 Discussion
The transmission rate of 34% found in this prospective cohort study is within the range
for cohorts from other parts of Africa, reported rates being between 20% to 45% (Lepage
1993, Lallemant 1994) and higher than the rates reported from studies in developed
countries (ECS 1992, Gabiano 1992, Nair 1993). Comparison among studies is difficult
because of differing methods for diagnosis of infection and for calculation of mother to
child transmission rates. However, even with standardization, the rates for Africa are
higher (The Working Group 1995). Comparison can be made between the rates for this
study and those from two other African studies: from Kigali, Rwanda (Lepage 1993) and
from Brazzaville, Congo (Lallemant 1994). These studies used the same criteria for
defining infection status and the same method for calculation of transmission rates (Dabis
1992) although the numbers in the study cohort are smaller. The transmission rate for this
study lies between the rate reported for Rwanda (25 %), and that for Congo (40.4%).
Since the mothers in this study were mainly asymptomatic at the time of delivery, this could
account for the lower rates than in studies from Congo (Lallemant 1994) and from Zambia
( Hira 1989) In the Congo cohort, women who were symptomatic were more likely to
transmit infection; while in the Zambian cohort, which had a very high transmission rate,
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53% of the women were symptomatic .
The pattern of antibody clearance observed in the study cohort was similar to that found in
other studies (Lepage 1993, Ryder 1989, Andiman 1990). Almost universal clearance was
achieved by 12 months' age, which can be used as a cut-off for diagnosis of vertical
transmission in this population. This is important since more sophisticated tests are not
readily available in most developing countries, where the only available laboratory
diagnosis is an antibody test.
The finding in this study that deliveries by caesarean section were less likely to transmit
infection was previously reported from an interim analysis of this same cohort (Moodley
1994). That deliveries by caesarean section were protective against transmission has been
shown by the large European Collaborative study (ECS 1992), but this has either not been
reported in African cohorts (Hira 1989, Lallemant 1994) or has been shown to have no
effect (Lepage 1993) While overall caesarean deliveries were shown to be protective in the
study cohort, a comparison between elective and emergency caesareans showed no
difference. However, the number of elective caesarean deliveries was small. A secondary
analysis on caesarean deliveries in this cohort found that the protective effect was not
increased if caesarean deliveries were undertaken prior to membrane rupture (Kuhn 1996).
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Studies have reported that risk of transmission with vaginal deliveries was increased if
deliveries occurred through an episiotomy or laceration where the infant was exposed to
maternal blood (ECS 1992, Boyer 1994). This effect was not observed for the study cohort
where a sianificant number of deliveries were associated with an episiotomy or tear.
St. Louis et al (St. Louis 1993) from Zaire reported an association between risk of
transmission and anemia in those women with low hemoglobin values, especially if the CD4
+ lymphocyte count was high. The present study has found that women whose hemoglobin
values were below 10g/d1 during pregnancy were at an increased risk of transmission. This
may reflect the effect of advanced subclinical disease, in which case it may serve as a marker
of disease state. Alternatively, it may be due to poor nutrition and general poor health of
the mother, in which case it presents the possibility of a simple intervention in pregnant
HIV infected women. This finding needs to be evaluated further together with
assessment of immune function during pregnancy. This would be of particular importance
if AZT were to be used as a means of intervention during pregnancy.
It is now accepted that transmission of HIV-1 occurs via breast milk; the magnitude of the
increased risk of breastfeeding, in women with established infection, is said to be 14%
(Dunn 1992). This risk must be balanced against the increased morbidity and mortality
associated with formula feeding in developing countries (Cutting 1993, Heymann 1990.
Nicoll 1995). In Africa, breastfeeding is the norm and in all the reported cohort studies,
breastfeeding was almost universal. In the study cohort, 16% of the women did not
breastfeed at all, the main reason being the need to return to work immediately after
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delivery. Although no significant protective effect from formula feeding was noted, the
numbers were small and a larger study with equal numbers of women in each group is
needed for clearer definition. In a study from Zaire breastfeeding did not increase risk of
transmission, and it was protective against the morbidity attached to common childhood
illnesses in developing countries (Ryder 1991). A similar observation was made in a study
from Rio de Janeiro (Collareda 1993). Studies from developed countries have usually
observed an increased risk, but in these countries, the proportions of women breastfeeding
are small (ECS 1992, Gabiano 1992). Breastfeeding was generally prolonged in most
infants in the present study, and it is significant that, to date, no child has seroreverted,
although late seroreversion, which has been attributed to prolonged breastfeeding, was
reported in other African studies ( Bulterys 1995, Datta 1992). A recent study from India
supports the finding of our cohort where no seroreversion occurred despite breastfeeding
(Kumar 1995). Unless suitable conditions are met for the provision of formula feedings to
infants of all infected women in developing countries (clean water, sterilization facilities for
bottles and nipples, adequate funds to buy formulas, etc.) the recommendations of the WHO
and UNICEF should be observed (WHO/UNICEF 1992, Nicoll 1995).
Disruption in the integrity of the placental barrier by co-infection with syphilis could
increase the risk of transmission (Andiman 1991). Researchers from New York as well as
from Baltimore have reported increased transmission associated with untreated syphilis
(Borkowsky 1992) and with other sexually transmitted diseases (Nair 1993). Several other
studies have not found this association (Lepage 1993, Boyer 1994, St. Louis 1993). In
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our study no increased risk was found for women with syphilis. This could be explained by
the policy of treating all women with syphilis during antenatal care. If the difference in
observations of associated risk was due to the treatment factor, this presents another simple
intervention for reducing transmission.
Goedert et al (Goedert 1989) reported an increased transmission risk for infants born before
37 weeks' gestation. and the European Collaborative Study reported an increased risk in
those infants less than 34 weeks' gestation (ECS 1992). This association has not been
observed in our study and in most other studies (Ryder 1989. Lallemant 1994, Boyer 1994,
St. Louis 1993, Blanche 1989, Lindgren 1991).
A recent report by Minkoff et al (Minkoff 1995) found that the risk of transmission with
vaginal deliveries was increased if membranes were ruptured for _^ 4 hours; this association
was not found in our cohort and in the small number of other studies where this has been
reported (Boyer 1994, St. Louis 1993, Connor 1994). Similarly, the lack of association
with parity in the study cohort is the same as that from several other studies (ECS 1992,
Hira 1989, Lallemant 1994, Nair 1993, Boyer 1994, St. Louis 1993).
Intervention programs for the interruption of vertical transmission in the study population
need to take into account the protective effect of deliveries by caesarean section.
However, deliveries by caesarean section are not without risks and morbidity. In addition,
in a hospital where the number of caesarean deliveries is already high (25% at the study
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hospital), the additional burden of delivering all HIV infected women by caesarean section
must be considered. Ideally, intervention should be non-invasive and due consideration
must be given to such simple measures as maintaining an optimal haemoglobin during
pregnancy and treating sexually transmitted diseases such as syphilis. The use of a drug
such as AZT which has been shown to decrease transmission (Boyer 1994, Minkoff 1995) is
an option to consider, but needs to be weighed against cost, availability, and the necessity
for close monitoring. Alternatively, the use of vitamin A, the deficiency of which may
increase transmission (Semba 1994) needs to be evaluated further as it would be an
additional simple and inexpensive intervention.
In conclusion, this study has found that the vertical transmission rate of HIV-1 for the
black population in Durban is high; that deliveries by caesarean section were protective
against transmission of infection, and that women with lower hemoglobins were more likely
to transmit infection. In addition it has shown that clearance of maternal antibodies is
virtually achieved by 12 months of age, and that this age could be used as a cut-off for the




BREASTFEEDING BY HIV-1 INFECTED WOMEN AND OUTCOME IN
THEIR INFANTS : A COHORT STUDY FROM DURBAN, SOUTH AFRICA
7.1 Summary
Background: Women in developing countries have the difficult choice of balancing the risk
of transmitting the human immunodeficiency virus through breastmilk against the substantial
benefits of breastfeeding. It is not known, however, whether the benefits of breastfeeding
are the same when the mother is HIV infected. Therefore, we examined the impact of
breastfeeding on infections, growth, and mortality in the infants of HIV-1 infected women.
Methods: Infants of HIV-1 positive women were followed up from birth and at each visit
were examined, growth parameters recorded, note made of feeding method, and of current
and interim illnesses.
Results: Of the 43 infected and 90 uninfected infants for whom feeding data was available,
36 infants (27%) were exclusively breastfed, 76 (57%) received mixed feeding, and 21
(16%) received formula only. The HIV transmission rate was 39% in those exclusively
breastfed, 24% in those on exclusive formula, and 32% in those receiving mixed feeding
(RR of 7.39, CI 1.67 - 32.6 between the exclusive breast and formula only groups). There
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was a stepwise increase in the transmission rate with duration of exclusive breastfeeding of
one. two, and three months (45%, 64%, and 75%, respectively). Among the infected
infants, 7(50%) exclusively breastfed, 13(51%) of those on mixed feeds and none on
formula only developed AIDS, exclusively breastfed infants had a slower rate of progression
to AIDS (mean age 7.5 months compared to 5.0 months, p=0.2242) than those on mixed
feeds. Mortality (which occurred in the infected infants only) was 19% in the exclusively
breastfed infants; 13 % in those on mixed feeds, and 0% in those exclusively formula fed.
The frequency of failure to thrive and episodes of diarrhoea and pneumonia were not
significantly different between the three groups, in both the infected and uninfected infants.
Conclusions: Exclusive breastfeeding by HIV infected women does not appear to protect
their infants against common childhood illnesses and failure to thrive, nor significantly delay
progression to AIDS. The implication of the trend towards differential mortality rates
according to feeding groups is uncertain and requires further investigation.
7.2 Introduction
One of the principal gains in maternal and child health during the past few decades has been
the revival of breastfeedina. The immediate and long-term benefits of breastfeeding have
been well documented (Howie 1990, Plank 1973, Victoria 1987, Cunningham 1977). The
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HIV epidemic, however, has made it impossible to have a uniform policy on breastfeeding
for rich and poor countries. There is clear evidence to show that HIV is transmitted
through breastmilk (Douglas 1992, Van de Perre 1993, Van de Perre1995) and the
increased risk of vertical transmission by this route is estimated to be about 14% for women
with established infection (Dunn 1992). Accordingly, in 1992, WHO made
recommendations on breastfeeding based on whether infectious diseases and malnutrition
were or were not the primary causes of infant deaths among populations (WHO 1992); in
developing countries HIV infected women were encouraged to continue breastfeeding. In a
more recent statement, UNAIDS has given far greater emphasis to ensuring individual
informed choice (UNAIDS 1996). This accords with the recognition that there are
circumstances in developing countries where alternatives to breastfeeding for HIV
seropositive women are a safe option (Nicoll 1994). Such circumstances might apply to
countries with intermediate economies, such as South Africa. Implications of breastfeeding
under conditions of varying, infant mortality rates, vertical transmission rates through
breastfeeding, HIV prevalence and incidence, have been modelled, and these calculations
may be useful to countries developing their own policies (Hu 1992). Although the dangers
of transmission of virus have been recognised, there is little information on whether
breastmilk of HIV seropositive women is as protective against common childhood
infections, malnutrition, progression to AIDS, and early death, as that of HIV seronegative
women. A recent editorial concluded that the lack of data on whether breast or bottle
feeding by HIV seropositive mothers affected overall outcome in their babies, limited
womens' choices in deciding on feeding method (Ziegler 1993).
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We report on the association between feeding practice and outcome in a cohort of children
born to HIV-1 infected women from Durban, South Africa.
7.3 Patients and Methods
This report is derived from a prospective, hospital based, cohort study on the natural history
of vertically transmitted HIV-1 infection. The study was conducted at King Edward VIII
hospital, a large urban hospital in Durban, KwaZulu/Natal. About 99% of the patient
population is black. The major causes of infant death in KwaZulu/Natal are infections,
malnutrition, and perinatal problems (SA 1995, SA Vit A CONS. GROUP 1996,). South
Africa is classified as a middle income country by the World Bank with a per capita income
of $2670.
7.3.1 Patient population: the sampling method has been described in detail in Chapter 3.
At no stage of the study were the mothers influenced against breastfeeding. The policy in
the neonatal unit during the study period was to advise mothers on the advantages of
breastfeeding. Women who chose to formula feed received advice on hygienic preparation
of feeds and were not provided with any financial support for artificial feeding. Method of
feeding was recorded in detail for the first twelve months; thereafter this assessment
became difficult as the children were either fully on family diet or complementary feeds
made up the major part of the diet. Feeding method was defined as: exclusive
74
breastfeeding: where the child was on breastfeeds only from birth ( these infants
received no supplementary milk feeds); mixed feeding: where the child was receiving
both formula feeds and breastmilk (the period of exclusive breastfeeding and the age at
which formula was commenced were noted, as well as the duration during which the
infant received both breast and formula feeds); exclusive formula feeding: where the
infant received formula feeds only. All groups of infants would have received other
complementary foods, for varying periods. These definitions vary from those
recommended (Labbok 1990).
The infants received no anti-retroviral or immunotherapy during the course of the study.
7.3.2 Classification
Classification of infection status was made according to the recommendations of the
Ghent workshop (Dabis 1993). Children were regarded as infected if they were
antibody positive at 15 months or had an HIV- related death. They were classified as
uninfected if the antibody test was negative from 9 months of age, or if death was non-
HIV related. Those infants who were lost to follow up before the age of nine months
whilst still antibody positive and those whose cause of death could not be determined,
were classified as indeterminate. The diagnosis of AIDS was based on the revised
WHO criteria (WHO 1989).
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7.3.3 Definition of morbidity
Diarrhoea, pneumonia, and otitis media were chosen as outcomes because these are the
infections that breastfeeding appears to prevent in non-HIV-infected populations, and
because diarrhoea and pneumonia are the common causes of morbidity and mortality in
black South African infants and children. The following criteria were used to define
morbidity :
Diarrhoea : three or more episodes of loose stool per day, present for at least three days.
Pneumonia : the presence of tachypnoea and crackles and/or radiological changes.
These three infections were chosen as they have been shown to be less common in
breastfed infants. Failure to thrive: weight and length below the third percentile or
crossing of percentile lines (NCHS 1976).
Otitis media : inflammation of the eardrum or a purulent discharge from the ear.
7.3.4 Laboratory methods
Blood samples were taken at regular intervals from birth. These were tested for HIV-1
antibodies by a commercial enzyme linked immunosorbent assay, ELISA, (Abbot
Laboratories); by a confirmatory Roche ELISA (Cobus Core) or an immunoflourescent
assay, IFA, (Virion). Samples were considered positive if the second ELISA or the MA
was positive. The same method was applied for maternal samples.
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7.3.5 Statistical methods
Social and demographic characteristics were compared between the three feeding method
groups using Analysis of Variance or Chi-square test. The association between feeding and
rate of HIV infection was assessed for maternal risk factors which could impact on
transmission, including age, parity, haemoglobin level, and mode of delivery (ECS 1992,
Borkowsky 1992, Gabiano 1992). The latter two were included as these were found to be
significantly associated with transmission in a previous report on this population (Bobat
1996). Logistic regression analysis was used to control for the effect of these variables on
the transmission rate and feeding method.
For mortality and progression to AIDS, survival function estimates were computed using
the product-limit (Kaplan-Meier) method. The curves were compared using the log-rank
test.
Morbidity was expressed. according to feeding practice and HIV status, as incidence
densities per 100 child months of follow-up.
7.4 Results
Between October 1990 and April 1993, 234 black infants and their 229 mothers were
entered into the study. Fifty three patients did not attend a single follow up visit and were
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excluded from the study. This group was not different from the rest of the cohort with
regard to maternal characteristics used to compare the groups .
7.4.1 Classification and vertical transmission:
The remaining 181 children were classified as 48 infected (including 17 deaths); 93 not
infected, and 40 indeterminate (including 8 deaths). The median vertical transmission rate
was 34% (confidence intervals 26%-42%); the upper estimate, which assumes all
indeterminates are infected, was 48%( 40% - 60%); the lower estimate, which assumes all
indeterminates are uninfected, was 26.5%(20% - 33%).
The mean follow-up period for the breastfed infants was 22.8 months, for those on mixed
feeding was 22.5 months, and for those on formula only was 20.6 months.
7.4.2 Feeding and transmission:
There were no significant differences in the basic social and demographic characteristics
between the women in the three different feeding-method groups (Table 7.1), as well as
between their newborn infants. The first available CD4 counts in the infants was at three
months of age; there was no significant difference in the means between those breastfed and
those on mixed plus formula only (2154, SD 1001 compared to 2271, SD 746).
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Table 7.1 Characteristics of HIV-1 seropositive expectant mothers and their
newborn infants according to feeding method employed for the infants
Exclusive breast mixed feeding formula only





mean p-2-M (mg/1) ##
% caesarean deliveries
% in safe environment#
Newborn Data
mean (3-2-M (mg/1)
mean HIV- IgA (OD)*
24 (4.6)** 25 (6.4) 23 (3.2)
1.0 (1.2) 1.25 (1.2) 1.11 (1.0)
10.8 (1.1) 10.8 (1.2) 10.2 (1.8)
1.24 (0.6) 1.53 (1.0) 1.65 (0.5)
30 56 14
72 60 79
1.7 (1.9) 2A7 (2.1) 1.00 (1.9)
0.13 (0.2) 0.08 (0.2) 0.09 (0.1)
# access to electricity, safe water and toilet facilities
## beta-2-microglobulin
* optical density
** figures in parenthesis represent standard deviation
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There were 133 infants for whom adequate feeding information was available.
Twenty one infants (16%) were exclusively formula fed, 36 infants (27%) received
exclusive breastfeeds and 76 (57%) received both breast and formula (mixed) feeds. The
median duration of exclusive breastfeeding for the whole group was 5.0 months (range 1 to
12 months), for those on exclusive breast was 12.0 months (1-12), and for those on mixed
feeds was 2.0 months (1-12).
When the relationship between feeding and transmission was analysed more closely (Table
7.2), it was found that infants who were exclusively formula fed had a lower transmission
rate (24%), as compared to those infants who received either mixed feeding (32%), or
exclusive breastfeeding (39%); the relative risk for infection in the exclusively breastfed vs
those on formula only, was 1.63 (CI 0.71- 3.76), p-value 0.24. The increased risk for
transmission by breastfeeding compared to formula feeding was 15% (CI 1.8 - 31.8).
Maternal risk factors which could impact on transmission were compared and were found
not to be different between the three groups. Mode of delivery, maternal age, and maternal
hemoglobin level had no impact on transmission rate by feeding group. When these were
controlled for in a logistic regression model, the association between increased risk and
exclusive breastfeeding remained, but was of borderline significance (relative risk 10.7, CI
1.1 - 96.0)
To determine whether duration of breastfeeding affected transmission, we assessed the risk
of infection according to the duration of exclusive breastfeeding, to the nearest month,
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Breast only 36 14 (39) 22 (61)
Breast and 76 24 (32) 52 (68) 1.63
formula (0.71 - 3.76)
Formula only 21 5 (24) 16 (76)
Total * 131 43 90
Numbers do not add up to 48 infected and 93 uninfected because of missing
data
Relative risk for infection in the exclusive breastfeeding vs exclusive formula
feeding
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(Table 7.3). The infection rates were 45% of those infants receiving breast only for the
first month. 64% of those receiving breast only for two months of life, and 75% of those
receiving breast only for three months. However there were only 4 infants in the latter
group. Thereafter the rate remained constant at ± 25% for up to 12 months of exclusive
breastfeeding. These figures are not statistically significant.
7.4.3 Feeding and mortality
Deaths occurred only in the infected infants. Of the 17 infected infants who died, 7 were
exclusively breastfed and 10 had mixed feeding. No deaths occurred in the exclusively
formula fed group during the study period, compared to a mortality of 19% (7/36) in the
exclusively breastfed infants, and of 13% (10/76) in the infants receiving mixed feeding,
Relative Risk 1.87 (CI 0.61 - 6.66). The relative risk of death in the exclusively breastfed
compared to the exclusively formula-fed, could not be defined, as there were no deaths in
those exclusively formula fed.
When we compared feeding vs mortality only in the HIV infected infants, we found
mortality to be highest in the infants receiving exclusive breastfeeds (7/14, 50%), compared
to 10/24 (42%) in the infants receiving mixed feeding and 0/5 (0%) in those infants
receiving formula only. However, survival at 12 months was similar in both the exclusively
breastfed and those on mixed feeding, 64% and 65%, (Figure 7.1).
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Table 7.3. The association between duration of exclusive breastfeeding and HIV





number infected transmission rate (%)
1 18 8 45
2 11 7 64
3 4 3 75
4-12 41* 15 25
*5 for <12 months and 36 for 12 months
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Figure 7.1 Mortality by feeding method
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7.4.4 Feeding and morbidity
Table 7.4 shows the relationship between feeding method and morbidity. The data shown
represents a total of 2924 child months of follow up. We found no significant difference
between the group that was exclusively breastfed and those who received mixed feeding and
exclusive formula feeding. This was similar for both the HIV infected as well as the
uninfected children.
7.4.5 Feeding and AIDS
Among the infected infants, 7/14 (50%) of those exclusively breastfed, 13/24 (54.1%) on
mixed feeding, and 0/4(0%) on formula only, developed AIDS during the study period
(Figure 7.2). Infants who were exclusively breastfed appeared to progress to AIDS more
slowly than those who received mixed feeds, mean age at diagnosis of AIDS was 7.5
months (SD 5.3, range 2-18 months), compared to 5.0 months (SD 2.0, range 3-10 months)
in the mixed feeding group, p-val = 0.2242.
7.4.6 The indeterminate group of infants
A similar pattern for morbidity to that detected in the infected and uninfected groups as
described above, was noted, little information was available for the 7 deaths in this group.
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Table 7.4 Morbidity according to feeding practice and HIV-1 status in infants
born to HIV-1 seropositive women






number 14 22 1
follow-up (months) 287 437 24
pneumonia# 6.27 (18) 8.70 (38) 0 0.76
(0.43-1.33)
diarrhoea# 10.5 (30) 13.5 (59) 0 0.81
(0.53 - 1.27)
otitis media# 3.8 (11) 3.60 (16) 0 1.10
(0.51 -2.37)
failure to thrive (%) 57.1 68.2 0 0.88
(0.51 - 1.49)
Uninfected infants
number 22 52 16
follow-up (months) 537 1246 393
pneumonia# 4.7 (25) 4.0 (54) 3.1 (12) 1.16
(0.73 - 1.83)
diarrhoea# 4.1 (22) 6.6 (82) 2.3 (9) 0.76
(0.48 - 1.21)
otitis media# 0.9 (5) 0.8 (6) 1 8 (7) 0.97
(0.32 - 2.98)
failure to thrive (%) 13.6 15.4 11.1 0.96
(0.29 - 3.18)
Figures are given as incidence densities per 100 child months of follow-up
Figures in parenthesis are the total number of episodes
CI : 95% confidence intervals
since the number of episodes of morbidity in the formula fed infected infants
was zero, calculation of relative risk would be meaningless; thus this group was
combined with the mixed feeding infants for the calculation of relative risk
numbers do not add up to 48 infected and 93 uninfected due to missing data
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In this prospective study of a cohort of babies born to black I-IIV-1 infected South African
women, we did not find the expected benefits of exclusive breastfeeding. We employed
four outcome criteria to measure benefit: mortality, infections, failure to thrive, and
progression to AIDS. Of the HIV infected children who died during the study period, the
mortality was highest in those exclusively breastfed, although it did not achieve statistical
significance. Our study does not allow us to determine the cause of this finding. This
ambiguity may be the result of research design: the study did not set out to test the effects
of breastfeeding against formula by a randomised controlled method. We have calculated
that the sample size in our population (ante-natal HIV-1 prevalence 20%) to detect
differences in mortality between breast and formula fed infants of HIV seropositive mothers
will be 2500 antenatal attendees (80% power, 5% significance level). Disturbances in
breastmilk immune factors directed at common infections of infancy and the impact of HIV
virions on gastrointestinal integrity require further investigation.
Morbidity due to common childhood infections (diarrhoea, pneumonia, otitis media) and
failure to thrive, were as frequent in babies who were exclusively breastfed as in those who
were given either exclusive formula or a mix of formula and breastmilk; this observation
held true for both HIV infected and HIV uninfected infants and children.
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To the best of our knowledge there are four other sets of similar data, some of which are
comparable to the results given here. Results from an Italian study (Tozzi 1990) showed
that breastfeeding was of short term advantage: progression to AIDS was slower and
survival longer in breastfed as opposed to formula fed HIV infected children. This
advantage of breastfeeding was lost when children were 5 years of age (De Martino 1992).
However, data were retrospectively collected and the duration of breastfeeding was not
known. In a study of relatively privileged Zairian women, breastfeeding was found to
protect the infants from common childhood illnesses, in those born to both HIV infected
and HIV negative women (Ryder 1991), but the HIV infected infants were not compared by
feeding method and all those who died within the first six months were excluded from the
analysis. The closest findings to ours are also from Africa. In a prospective study from
Nairobi, breastfeeding by HIV infected women, for longer than 15 months, was more often
associated with growth retardation than breastfeeding for shorter periods (Datta 1994).
Gray et al have reported an increased transmission rate and an increased mortality in
exclusively breastfed HIV infected infants from Soweto, South Africa (Gray 1996). In
breast fed infants, mortality was 9/114(7.0%), compared to 1/49(2%), in infants on mixed
feeding (p=0.14). Moreover, there were no adverse effects on growth or morbidity, and no
increase in hospital admissions among breastfed over non-breastfed infants born to HIV
seropositive women.
The higher transmission rate in the exclusively breastfed group compared to either the
mixed breast and foilnula fed group or to those exclusively formula fed, is similar to
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findings summarised in a recent meta analysis on this subject (Dunn 1992). There are
several studies from the developed countries as well as from Africa that have reported on
the association between breastfeeding and transmission of HIV infection (De Martino
1994. Ryder 1991, ECS 1992). An increased risk of transmission through breastfeeding
has been reported from Brazil, a country with an intermediate economy (Collareda 1993).
The Italian study also showed that the risk of transmission was increased with
breastfeeding and that the risk increased with the duration of feeding (De Martino 1994).
The data from Durban do not reach statistical significance but are suggestive of a similar
direction in the relationship between HIV transmission and duration of breastfeeding.
The greater prevalence of infections and failure to thrive among the HIV infected patients
was predictable and extends the results from other studies in developing (Mgone 1991) and
industrialised countries (ECS 1991). It is essential that the trend towards an association
between breastfeeding and HIV related mortality (detected in both Durban and
Johannesburg) and the absence of data for HIV unrelated deaths (given the small number
of deaths in the indeterminate group) be explored further.
Recent reviews of the available published data on the subject of breastfeeding have
confirmed once again that breastfeeding protects against infections and reduces infant
mortality; the conclusion was drawn that the relative risk for mortality of artificial feeding
was from one to nine (Nicoll 1994). These findings generally apply to developing and
developed countries. However, most studies on breastfeeding were undertaken in the pre-
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HIV era. As the benefits of breastfeeding were well established, we did not include a
control group of HIV seronegative pregnant women and their offspring.
This study has several shortcomings which require explanation. The women were not
randomly allocated to breastfeeding versus no breastfeeding, they self-selected to feeding
method. It has been argued, among key research scientists, that randomised studies in
poor countries will be unethical (Nicoll 1994) given the undisputed public health benefits of
breastfeeding and the prospects of allocating women without access to adequate sanitation
and clean water to a non-breastfeeding group, and women with such access to breastfeeding
with its concomitant risk of HIV transmission. Secondly, the number of women who chose
exclusive formula feeding was small; therefore the number of HIV infected infants in the
artificially fed group was minuscule. This, in fact, is the real position in Africa; very few
women give only formula feeding. The pattern of feeding adopted by the women in this
study is similar to that for most women in Africa (Nicoll 1994). In addition, we were
unable to assess the possible role of other contributing factors to the results obtained; these
include maternal viral load, CD4/CD8 counts, and p24 antigen levels (Peckham 1995). We
could not assess whether the differences in time to AIDS between breastfed and formula fed
infants were due to dissimilarities in the proportions infected in-utero, intra-partum, and
postnatally. We have data which suggests that the proportions of infection in our cohort
were: 27% in-utero and 72% durirg delivery and postnatally (Moodley D, Coovadia H,
Bobat R, Sullivan J. Timing of vertical transmission of HIV by polymerase chain reaction.
Submitted for publication.). The delay to AIDS in the breastfed infants may have been due
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to these being infected by breastmilk in contrast to those on formula who could have been
infected earlier. It should be noted that the comparison of time to AIDS by feeding method
was limited, as we did not control for confounding factors.
The inclusion of the indeterminate group of infants is unlikely to have altered the main
conclusions of the study. The proportion of these infants in the different feeding groups
resembled that in the 141 infants classified as infected or uninfected. The maternal
characteristics, newborn and early infancy features in this indeterminate group, were similar
to those included for analysis. Moreover. morbidity patterns were similar, and the available
information suggests that there were no differences in morbidity between those infants
breastfed and those receiving formula or mixed feeds; the seven deaths in this group may
have added clarity to the mortality differences between the groups.
In a recent workshop on breastfeeding in HIV positive women (held in Durban, South
Africa), health professionals from central, east, and southern Africa, agreed that there was
no conflict of purpose in safeguarding individual choice whilst promoting breastfeeding at
population level. The results from this study do not contradict this consensus view, and
they support the recent UNAIDS recommendations (UNAIDS 1996).
In conclusion, our findings have particular relevance to populations in countries with
intermediate economies where the under five mortality rates straddle the division between
high and moderate (The World Health Report 1996); and HIV infected women can choose
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safe alternatives to breastfeeding. In these situations, all pregnant women should be
offered counselling and HIV testing, and those found to be positive to be advised that
breastfeeding may not provide the anticipated degree of protection against common
infections and growth failure, and is associated with a higher risk of transmission. We
expect that breastfeeding would regain its role as the pre-eminent method of infant feeding,




NEONATAL CHARACTERISTICS AND OUTCOME IN A COHORT OF
INFANTS BORN TO HIV-1 INFECTED AFRICAN WOMEN FROM DURBAN,
SOUTH AFRICA
8.1 Summary
Background: Most newborns of HIV-1 seropositive women show little evidence of HIV
disease. The early identification of vertically infected infants at risk of rapid progression and
death enables appropriate management of these infants. In developing countries, where
techniques such as viral load are unavailable, emphasis has to be placed on clinical
manifestations.
Methods: HIV-1 seropositive women were identified antenatally, and their newborn infants
followed up from birth to early childhood. At birth, the infants' growth parameters were
measured, they were examined clinically, and note was made of any problems related to
delivery and resuscitation measures. Complications arising during the neonatal period were
recorded on discharge.
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Results: The final cohort comprised 48 infected and 93 uninfected infants. There were no
differences between the newborns who were later found to be infected, compared to those who
were exposed, but uninfected, with regard to growth parameters, frequencies of preterm, low
birth weight, and growth retardation rate, as well as for neonatal complications. However,
when we compared the newborn data of those HIV-infected infants who died by 18 months,
with that of those infected infants who survived, we found the former group had lower mean
birth weights (2.90kg, 3.15kg, p=0.096) and lengths (46.5cm, 48.5cm, p=0.041), had a higher
frequency of low birth weight (30.8%, 3.3%, p=0.024), were more likely to have been
resuscitated (30.7%, 0%, p=<0.001), and were more frequently jaundiced (46.2%, 13.3%,
p=0.044).
Conclusions: As a group, vertically infected newborns of HIV-positive mothers cannot be
differentiated from those who are exposed, but uninfected. However, infected newborns of
HIV-positive women who are found to be growth retarded, or who develop complications in
the neonatal period, are more likely to progress rapidly and die, and should therefore be
monitored carefully and managed vigorously, and may be suitable for participation in trials




In children, infection with the human immunodeficiency virus, type 1 (HIV-1) occurs chiefly
by vertical transmission, either in utero, during labour and delivery, or post partum by
breastfeeding (Mofenson 1994, Douglas 1992, Borkowsky 1992 ). The majority of
transmission in developing countries occurs during labour and delivery and through
breastfeeding, and therefore infected newborns of HIV-1 seropositive women show few, if
any, abnormalities or evidence of HIV disease (Lepage 1991, Bulterys 1994, Lallemant 1989).
Some studies from developed countries have found differences in growth parameters at birth,
and higher frequencies of preterm deliveries and low birth weights (Spinillo 1994, ECS 1991).
Less information is available for Africa, and data from Rwanda and Malawi show conflicting
results (Lepage 1992, Taha 1995). It is clear from recent evidence that babies who have very
high viral loads within 48 hours of birth and have probably been infected in-utero, have rapid
progression of disease compared to those who have lower viral loads (Shearer 1997).
The detection of HIV infection in the newborn, which requires molecular amplification
techniques, is beyond the resources of developing countries and most diagnoses during
infancy are made on the basis of WHO clinical criteria and the presence of antibodies beyond
15 months of age. For many reasons (such as prophylaxis, early therapy, counselling, etc) it is
advantageous to detect HIV infection in babies of seropositive women soon after birth, and to
identify those at risk for rapidly progressive disease.
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Therefore, we examined the neonatal characteristics of infants, born to H1V-1 infected black
women from Durban, South Africa, who were followed-up from birth to early infancy,
particularly to detect clinical features predictive of rapid progression.
8.3 Patients and Methods
Details of the sampling method have been previously described in Chapter 3.
8.3.1 Patient population:
All liveborn infants of those women testing HIV- positive were entered into the study, with
maternal consent. Data on maternal age, parity, obstetric history, antenatal care and
circumstances around labour and delivery, as well as results of haemoglobin and syphilis
serology, were obtained from the newborn infants' records, and retrospectively from the
obstetric charts. Gestational age was assessed from ultrasonography done at the first antenatal
visit. The mothers received no antiretroviral treatment or vitamin A supplementation, either
during, pregnancy or post delivery.
All the newborn infants were examined within 48 hours of birth. A full clinical examination was
performed, with assessment of each system, growth measurements recorded (weight, length,
head circumference), and note made of any dysmorphism. Before discharge, any complications
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occurring during the hospital stay were recorded. Initial blood samples were taken at this time.
The infants were followed up at regular intervals to early childhood .
8.3.2 Classification of infection status
Refer Chapter 3 .
8.3.3 Laboratory methods
Refer Chapter 3 .
8.3.4 Statistical methods
Infected babies were compared to non-infected babies using Student's unpaired t-test for
continuous data and Chi-square test (or Fischer's exact in the case of small cell sizes) for
categorical data.
The same tests were used for comparing babies who died to those who survived. The
significance level was set at 0.05.
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8.4 Results
Between October 1990 and April 1993, 234 black infants and their 229 mothers were entered
into the study. All the children were born at least 18 months prior to the analysis .
53 infants who were not brought for a single follow-up visit were excluded from the study.
The final cohort comprised 181 patients who were classified as: 48 infected, 93 not infected
and 40 indeterminate. The vertical transmission rate was 34% (95% CI 26-42%).
The mean follow-up period for the infected infants was 28.5 months, and for the uninfected
infants was 23.6 months.
8.4.1 Maternal data
The mean age of the mothers was 24 years (range 16 - 40 years), 32% were primiparous, 18%
had a positive syphilis serology, and 35% were delivered by caesarean section. Sixteen percent
of all deliveries occurred before 37 weeks' gestation. There was no history of intravenous drug
abuse. The mothers were from uniformly poor socio-economic circumstances. At the time of
delivery, only 5 mothers had any HIV- related symptoms, and none fulfilled the WHO criteria
for AIDS. There were two maternal deaths in the puerperium, both non HIV- related.
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8.4.2 Clinical and laboratory characteristics
There were no differences between infants who were later found to be infected, compared to
those who were exposed but uninfected, with regard to the parameters shown in Table 8 1.
8.4.3 Neonatal complications
Complications occurring during the newborn period were compared in the two groups. These
are shown in Table 8.2. There were no other substantial differences between the two groups.
8.4.4 Neonatal characteristics of those who subsequently died:
All the above clinical characteristics, complications, and laboratory data were compared in
those infected infants who died by 18 months, with those who were infected, but survived,
beyond 18 months (Table 8.3). The infants who subsequently died, had lower mean birth
weights and lengths, were more likely to be low birth weight, were resuscitated more often, and
more frequently had jaundice or sepsis than those who were alive at the end of 18 months. The
rest of the features were not significantly different between the groups.
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3.06 (0.37) 3.07 (0.64) 0.908
47.7 (2.66) 48.5 (2.82) 0.163
34.2 (1.16) 34.5 (2.83) 0.459
3 (6.2%) 10 (10.9%) 0.542
10.4 16.1 0.357
6 (12.5%) 14 (15.2%) 0.663
21 (45%) 53 (57%) 0.168







% low birth weight
(<2500 g)
small for gestational age
females
total globulin (g/dl)*
figures are means and standard deviations
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Table 8.2. Complications in the neonatal period in 48 infected and 92













5 (10.4) 14 (15.2) 0.431
2 (4.2) 4 (4.3) 1.000
15 (31.3) 19 (20.7) 0.165
12 (25) 22 (23.9) 0.887
0 (0.0) 7 (7.6) 0.095
1 (2.1) 3 1.000
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Table 8.3. Neonatal characteristics and complications in those HIV-1 infected














< 2500 gr 4 (30.7%) 1 (3.3%) 0.024
Resuscitated 4 (30.7%) 0 (%) <0.001
mean APGAR @ 1 minute 7.6 (1.8) 8.8 (0.6) 0.112
Jaundice 6 (46.2 %) 4 (13.3%) 0.044
Sepsis 6 (46.2%) 6 (13.9%) 0.137
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8.4.5 Comparison of neonatal data:
Neonatal data from studies done in both developed and developing countries are presented in
Table 8 4, to show the similarities and differences between regions.
8.5 Discussion
It is important to detect abnormalities and HIV infection in the neonatal period as optimal
utilisation of appropriate health and welfare services can be ensured, prophylaxis against
common infections provided, likely clinical problems anticipated and effectively managed
(diarrhoea, pneumonia, malnutrition), prognosis discussed, and advice on breastfeeding given.
General birth data (perinatal and neonatal mortality, low birth weight and prematurity ) for
statistical, surveillance and monitoring purposes, can be adjusted to account for the impact of
HIV infection.
In this prospective cohort study where we examined birth and neonatal characteristics of infants
born to HIV-1 positive women, we found no significant differences between the infected and
uninfected groups with regard to intrauterine growth, prematurity, and neonatal complications .
These findings are similar to the available data from several other studies. Reports from Italy,
France, Sweden, and USA (Spinillo 1994, Blanche 1989, Lindgren 1991, Nesheim 1994) found
no differences in the growth parameters, preterm and low birth weight rates, and frequency of
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Table 8.4 Comparison of neonatal characteristics and complications of HIV-
infected (inf) and uninfected (n/inf) infants born to HJV-1 positive
women from developed and developing countries
Newborn South Africa Rwanda USA Italy France
feature (Durban) (New York)
inf n/inf inf n/inf inf n/inf inf n/inf inf n/inf
mean 3.06 3.07 2.68 2.91 2.53 2.86 2.91 2.96 2.96 3.04
weight
(kg)
mean 47.7 48.5 47.3 48.0 n/a n/a 48.4 48.7
length
(cm)
mean 34.2 34.5 34.6 35.1 32.0 33.1 n/a 33.5 33.9
OFC*
(cm)
% preterm 6.2 10.9 42 32 33 19 15 16 15 11
% low 10.4 16.1 22 14 45 29 21 18 22 14
birth
weight




complications between infants who were HIV-infected and those who were exposed, but
uninfected. However, there are other studies which did identify differences between such
groups, In Miami, New York, and Baltimore (Hutto 1991, Abrams 1995, Nair 1993) infected
infants were more likely to have evidence of growth disturbance, to be preterm, or to have
higher frequencies of complications such as sepsis. The European Collaborative Study showed
a strong correlation with extreme prematurity and increased risk of transmission (ECS 1992).
Information on newborn characteristics from Africa is limited. Two studies, from central Africa,
compared neonatal data of babies born to HIV-seropositive women, depending on whether or
not the infant was later found to be infected. The study from Rwanda (Butlerys 1994) found
that infected newborns were more likely to have lower birth weights and lengths, and were
more frequently preterm and low birth weight, whilst the other, from Malawi (Taha 1995),
compared only growth, and found no differences. What all the studies agree on is that there is
no characteristic clinical syndrome which identifies the HIV- infected child at birth.
Several studies, mainly from Africa and Haiti, compared the outcomes of infants born to HIV-1
seropositive and 1-11V-1 seronegative mothers. Whereas the study from Congo found no
differences in the neonatal characteristics of these two groups (Lallemant 1989), the reports
from Rwanda and Malawi found that infants born to HIV-1 positive mothers were more likely
to have lower birth weights and lengths, and had an increased frequency of preterm delivery
and growth retardation (Lepage 1991, Taha 1995); in addition, the study from Malawi reported
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a higher mortality rate in the children born to seropositive women. In the report from Haiti, it
was found that newborns of HIV-1 seropositive women had lower birth weights and a higher
frequency of preterm deliveries as compared to those born to HIV-1 seronegative women
(Halsey 1990). In a community-based study done in Durban, South Africa, at a time when the
HIV-1 seroprevalence was less than 5%, it was found that the mean birth weight for black
babies was 3.3 kg (SD 0.5 ), and the rate of low birth weight was 5% (Ramkissoon 1991). In a
report from the neonatal unit of the study hospital, the low birth weight rate was found to be
17.4% in 1990 (Adhikari 1995). Although these findings are not directly comparable to the
cohort of babies born to HIV positive women described here, they reveal no marked differences
between newborns of HIV positive and negative women.
When we compared infected infants who died with those infected infants who survived, we
found lower mean birth weights and lengths, higher frequency of low birth weight , more
frequent resuscitation at birth, and more cases of jaundice in the former. These differences,
most of which were detected within 48 hours of birth, were unexpected, but are consistent
with available data from developed countries. In a study from France, it was suggested that
the infants who developed rapid onset of severe disease were likely to have been infected in-
utero (Mayaux 1996). A recent study from the Women and Infants Transmission Study group.
Baltimore, has suggested that a higher HIV viral load may be responsible for early, rapid
progression of some vertically infected infants (Taha 1995). Studies from New York and
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Malawi found that mortality in their cohorts was strongly associated with prematurity (Abrams
1995, Taha 1995). The explanations for this vary, but may be linked to early infection with
high viral loads, or to an immature immune system at birth, enabling greater viral replication
and rapid progression of disease.
The type of complications which these newborns had suggest an intrauterine, rather than an
intrapartum or postpartum, insult. The limited information we have does not allow us to infer
the nature of this damaging event. It could be a high viral load in the mother or foetus,
placental dysfunction, or a concomitant sexually transmitted disease. When comparing studies
from developed countries with those from Africa, it is worth noting that, in most studies from
developed countries, large numbers of HIV-infected mothers were intravenous drug abusers,
and many received antiretroviral therapy, which may be confounding factors. In Africa,
intravenous drug abuse in young black women is rare: the majority of the women are HIV-
infected by heterosexual transmission; and the use of antiretroviral therapy is virtually non-
existent. However, African women are exposed to certain risk factors such as micronutrient
deficiency, amniotic fluid infection syndrome and sexually transmitted diseases, which may
increase the risk of intrauterine HIV transmission, and have negative effects on intra-uterine
growth (Borkowsky 1992, Nair 1993, Semba 1994).
108
In summary, in this prospective cohort study of newborns born to HIV-1 infected women, we
have found that, as a group, there were no significant differences in growth parameters and
neonatal complications between the infants who were HIV-infected compared to those who
were exposed but uninfected. However, when we examined the group of HIV-infected infants
who subsequently died, we found that they had lower birth weights and lengths, were more
likely to be low birth weight, and had higher frequencies of complications in the neonatal
period. These simple clinical criteria may help to identify a group of HIV-infected infants born





THE EARLY NATURAL HISTORY OF VERTICALLY TRANSMITTED
H1V-1 INFECTION IN AFRICAN CHILDREN FROM DURBAN,
SOUTH AFRICA
9.1 Summary
Objectives: To determine the natural history of vertically transmitted HIV infection in
South African children.
Patients and methods: Infants born to HIV infected women were followed up from birth
to early infancy. At regular intervals, the infants were examined, growth and development
assessed, all current and interim illnesses recorded.
Results: There were 48 infected and 93 uninfected infants; the mean period of assessment
was 26 months. The mean age at onset of signs was 5.1 months for infected infants, and 9.2
months in uninfected infants; of the former, 70% were symptomatic by 6 months. The
relative risks in the infected infants were highest for lymphadenopathy (4.56; Cl 2.7-7.7),
failure to thrive (4.48; 2.57-7.81), and neurological abnormalities (3.32; 1.96-5.58); the
most frequent findings were diarrhoea (occurred in 78%), pneumonia(76%) and
lymphadenopathy (70%). Thrush and pneumonia occurred early, but declined over time,
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whereas diarrhoea and neurological abnormalities occurred later and increased in frequency;
lymphadenopathy and hepatosplenomegaly remained constant. Of those who developed
AIDS, the mean age at onset was 5.95 months, with 95% diagnosed by 12 months. The
mortality in infected infants was 35.4%, and 76% of deaths occurred within the first year.
About two thirds of HIV infected infants survived into early childhood, mean survival 34.1
months.
Conclusions: In South African children with vertically acquired HIV-I infection, the onset
of disease is early and deterioration to AIDS and death are rapid. Infected infants can be
easily recognised clinically, the majority by 6 months of age, which is particularly useful in
developing countries. Two thirds of infected infants survived beyond infancy; this has
important implications for management and health care planning.
9.2 Introduction
Human Immunodeficiency Virus ( HIV1) infection masquerades in the guise of such a
multiplicity of disorders that it has raised the level of diagnostic uncertainty in clinical
medicine as did tuberculosis and syphilis. Despite the substantially higher burden of
sickness and death due to perinatally transmitted HIV in poor countries, we know more
about these problems in industrialised countries than in the former. Descriptions from the
European Collaborative Study (ECS 1994, ECS 1991) together with reports from the
Italian multicentre study (Italian Multicentre Study 1988, Italian Register 1994) and from
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France (Blanche 1990), and accounts from a few major cities in the USA (Johnson 1989,
Scott 1989) and the United Kingdom (Mok 1989), have established a recognisable clinical
picture of paediatric HIV infection in the western hemisphere. It is unclear whether
factors such as differences in routes of transmission to women, in subtypes of the virus, in
prevalence of sexually transmitted diseases and nutritional deficiencies, and genetic
variation, influence the expression of HIV disease among children in developing countries.
There are very few prospective cohort studies of the natural history and clinical profile of
perinatally transmitted HIV from the latter. Those that have been undertaken in Africa
have been largely restricted to central and east Africa (Datta 1994, Lepage 1990, Lallemant
1989) and are insufficient to enable clinicians to develop a consistent pattern of the
disease. Indeed, a recent paper lamented the lack of studies which adequately documented
the survival and experience of HIV infected children (Meyers 1994).
Knowledge of the natural history of vertically transmitted HIV-1 infection is essential for
appropriate care of infected children, for prognostication (Forsyth 1996), choice of patients
likely to benefit from antiretroviral therapy and to enable the formulation of suitable
management policies. This information is also necessary for the planning of clinical trials
and immunisation against HIV infection.
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9.3 Patients and Methods
This report is derived from a prospective, hospital based, cohort study conducted at a large
urban hospital in Durban. All the children in the study were born at least 18 months prior to
the analysis.
9.3.1 Patient population
The sampling method has been described in detail in Chapter 3.
Mothers were asked to bring the child to the follow up clinic for any problem, so that
episodes of illness would not be missed. The women were reimbursed for transport costs
to encourage follow up visits. At no time during the study did the children receive anti-
retrovirals, immunotherapy, or prophylaxis against pneumocystis carinii.
9.3.2 Classification
Refer Chapter 3 for details .
9.3.3 Definition of morbidity
The following criteria were used to define morbidity:
Diarrhoea : three or more episodes of loose stool per day, present for at least three days.
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Pneumonia : the presence of tachypnoea and crackles and/or radiological changes. Thrush:
if both the hard and soft palate were involved and/or present in more than one site.
Lymphadenopathy: if present in more than one site and at least 0.5 cm in diameter.
Neurological abnormalities: the presence of static or delayed development/or regression of
milestones, tone disturbances and seizures (in the absence of infection). Failure to thrive:
weight and length below the third percentile on more than one occasion / or crossing
percentile lines (NCHS 1976). Hepatosplenomegaly: if present on more than one
consecutive visit. Fever: if present for more than three days/ or if recurrent. Skin rash: any
significant rash other than impetigo and scabies.
9.3.4 Laboratory methods
Refer Chapter 3 for details.
9.3.5 Statistical methods
Relative risks were calculated for the comparison between occurrences of morbidity in the
HIV infected children relative to uninfected children. The chi-square test was used to
assess the significance of the associations. Incidence densities of morbidity per 100 child
months of follow-up were estimated for the two groups and Relative risks and 95%
confidence intervals were calculated. Kaplan-Meier estimates were calculated to estimate
the average age at onset of morbidity, development of AIDS, and mortality, and were
compared using a Log-rank test.
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9.4 Results
9.4.1 The cohort: between October 1990 and April 1993, 234 black infants and their 229
mothers were entered into the study. All the children in the study were born at least 18
months prior to the time of analysis. Those who did not attend a single follow up after birth
were excluded from the study. there were no differences between this group and the
remaininc„, cohort, as previously described (Bobat 1996). The final cohort comprised 181
infants. The children were followed up for varying periods, ranging from 1 to 48 months.
The mean follow up period for the infected infants was 28.5 months, and for the uninfected
infants was 23.6 months.
9.4.2 Classification
The children were classified as 48 infected (including 17 deaths); 93 not infected, and 40
indeterminate(including 8 deaths). The vertical transmission rate was 34% (95% CI
26% - 42%). There were no late seroconverters during the study period.
9.4.3 Onset of disease
In all the following, analyses. children with indeterminate status were excluded. The data
presented here represents a total of 3234 child months of follow up. The mean interval
between birth and the onset of symptoms in infected infants was 5.1 months (range 1-21
115
months); in contrast, infants who were exposed but not infected manifested symptoms at a
mean age of 9.2 months. By 3 months, 60% of infected infants showed some form of HIV
related sign/symptom, by 6 months 70% manifested HIV related signs, whilst at age 1 year.
77% were symptomatic. The mean age at onset of the various morbidity criteria is shown in
Table 9.1. Infected children had an earlier onset of lymphadenopathy, pneumonia,
neurological disturbances and failure to thrive as compared to the children who were
exposed but not infected.
9.4.4 Disease patterns
Morbidity is reflected in four formats: as the proportions of infants affected by the clinical
signs, as frequencies of the specific signs, as frequencies per quartile in the first 12 months,
and as incidence densities of signs per 100 child months. Table 9.2 shows the frequency of
occurrence of the major morbidity criteria, the proportions of children affected by these
criteria, and the relative risks for their development in the infected versus the uninfected
children. There was a significantly increased risk for all the morbidity criteria, except fever
and skin rash, in the infected children. Diarrhoea and pneumonia were the most common,
occurring in 78% and 76% of all infected infants, with lymphadenopathy being found in
70% of those infected. Although infants who were exposed but not infected had high
frequencies of diarrhoea and pneumonia, these were not as common as in the infected
group. Failure to thrive occurred in 64% of infected infants, whilst only 14% of the
uninfected infants failed to thrive. Overall, neurological abnormalities were found in 58% of
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Table 9.1. Age at onset of signs of disease in infants born to HIV-1 infected women




thrush 2.14 (2.49) 1.8 (2.46) 0.660
hepatosplenomegaly 3.90 (3.47) 2.27 (1.17) 0.049
pneumonia 4.71 (1.77) 5.72 (5.63) 0.493
lymphadenopathy 5.08 (4.32) 6.50 (4.27) 0.331
neurological 5.44 (3.36) 9.07 (4.1) 0.009
abnormality
diarrhoea 6.74 (6.05) 6.78 (5.95) 0.976
failure to thrive 7.26 (3.97) 12.46 (2.69) 0.0002
SD: standard deviation
Table 9.2. Frequency of occurrence of signs of disease in children born to
HIV-1 infected women
117
Clinical sign Infected Not Infected Relative Risk p- PPV*
value
n=48 (%) n=93 (95% C I #)
lymphadenopathy 26 (70) 14 (15) 4.56 0.001 65
(2.70 - 7.75)
failure to thrive 25 (64) 13 (14) 4.48 0.001 65.8
neurological




hepato/splenomegaly 22 (61) 18 (20) 3.08 0.001 55
(1.89 - 4.52)
thrush 22 (61) 20 (22) 2.77 0.001 52.3
(1.75 - 4.44)
pneumonia 28 (76) 43 (47) 1.60 0.003 39.4
(1.20 - 2.12)
diarrhoea 29 (78) 52 (56) 1.38 0.020 35.8
(1.08 - 1.77)
skin rash 22 (61) 59 (64) 1.04 0.750 27.2
(0.77 - 1.42)
fever 28 (68) 56 (62) 0.79 0.081 33.3
(0.62 - 1.00)
# confidence interval *PPV positive predictive value
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infected infants and in 17% of those uninfected. In both the infected and the uninfected,
developmental disorders accounted for the majority of neurological problems after the first
three months.
Figures 9. la and 9. lb show the progression of the clinical signs over 3 monthly periods
during the first year in the infected and uninfected groups. In the infected group, thrush was
common initially but declined after 6 months age; lymphadenopathy and
hepatosplenomegaly remained consistent findings throughout; the frequency of pneumonia
declined after the first 6 months; whilst neurological problems and diarrhoea increased over
the course of the year. A similar pattern was noted for the uninfected infants, although the
frequencies were far lower for all the clinical signs assessed.
Table 9.3 compares the morbidity criteria as the incidence densities per 100 child months
of follow-up, between the two groups. This shows the significantly higher incidence for all
the criteria, except pneumonia, in the infected group.
9.4.5 Progression to AIDS:
The diagnosis of AIDS was made in 44.4% of infected infants by age 1 year and 46.8% by
age 18 months (figure 9.2). Of those who developed AIDS during the course of the study,
95% were diagnosed by age 12 months, mean age at diagnosis 5.95 months (SD 3.61
months, range 2-18 months) with no new diagnosis of AIDS being made after the first 18
months. The estimated mean age at diagnosis of AIDS for the entire group, taking into










Figure 9.1(a) Frequencies of clinical signs in quartiles,
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Figure 9.1(b) Frequencies of clinical signs,in quartiles,
over first year, in uninfected infants.
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Table 9.3. Incidence Density per 100 child months (number of episodes)
of signs of disease in children born to HIV-1 infected women






Thrush 6.94 (72)# L50 (33) 4.63
(3.07 - 6.98)
Failure to thrive 2.41 (25) 0.59 (13) 4.08
(2.09 - 8.00)
Lymph- 2.41 (25) 0.64 (14) 3.77
adenopathy (1.97 - 7.22)
Neurological 1.93 (20) 0.73 (16) 2.64
abnormalities (1.37 - 5.09)
Hepato- 2.12 (22) 0.81 (18) 2.59
splenomegaly (1.39 - 4.82)
Skin Rash 9.55 (99) 5.46 (120) 1.75
(1.34 - 2.28)
Diarrhoea 9.06 (94) 5.28 (116) 1.72
(1.31 - 2.25)
Fever 7.91 (82) 4.73 (104) L67
(1.24 - 2.24)
Pneumonia 5.49 (57) 4.09 (90) 1.34
(0.96 - 1.86)
* CI : confidence intervals # number of episodes
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consideration those who had not developed AIDS during the follow-up period, was 12.4
months (SE 1.01 months) .
9.4.6 Mortality
There were 17 deaths which occurred only in the HIV infected infants. The mortality rate
was 35.4%, with 76% of the deaths occurring within the first year of life (figure 9.3). The
mean age at death was 8.9 months (range 1-48 months). There were 4 late deaths which
occurred at 24, 24, 25 and 48 months.
9.4.7 Features in early childhood
The mean survival time for the HIV-infected group was 34.17 months. 35 infected infants
survived beyond the first 12 months. Of these, 25 were followed up beyond 2 years of age.
Of the 9 infants who were asymptomatic at 12 months, 3 developed minor symptoms/signs
during the second year of life (occasional diarrhoea or pneumonia, minimal
lymphadenopathy ) and six remained asymptomatic. Of the remaining 16 infants, 4 died, 1
developed AIDS and 12 stabilised and remained generally well, although most had
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Figure 9.2 Progression to AIDS, with 95% confidence intervals, in infected children
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Figure 9.3 Survival from birth, with 95% confidence intervals, in infected children
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9.4.8 Indeterminate group of infants
There were 40 infants in this group, including eight who died from unknown causes. Two
infants, who were HIV negative at six months and subsequently lost to follow-up, could
probably be regarded as uninfected, since, from our own experience we have found that
there were no seroreverters in our cohort (Bobat 1996). 16 infants were followed-up for at
least 6 months before being lost to follow-up whilst still antibody positive: of these, 5 would
be classified as infected based on the onset and pattern of disease described above, and 11
others would be uninfected. The remaining 15 infants were less than 6 months when lost to
follow-up and had insufficient information for further classification. We would then have a
cohort of 53 infected and 106 uninfected infants, giving a vertical transmission rate of
33 3%, which is similar to that previously calculated for this cohort (Bobat 1996).
9.5 Discussion
This is one of few detailed descriptions of the evolution of clinical features and mortality in
children born to HIV infected African women, derived from a cohort of babies
prospectively studied from birth to a minimum of 18 months. It therefore contributes to the
construction of a clearly discernible, and often distinct, pattern of morbidity and death in
HIV-1 infected and HIV-1 exposed but uninfected children in Africa, which has the global
burden of such infected children (Novelli 1996). The data also add to the existing body of
information on this disease, which has in the main been obtained from studies of European
and American children. The principal feature which distinguishes this disease in the African
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children reported here from those in the industrialised countries is the faster tempo of
disease progression. Indeed, given the substantial differences in the economic, social and
health related backgrounds of the populations in which these children are born and grow up,
it is surprising how closely the disease profiles, in most other respects, resemble each other.
There are likely to be many reasons for the rapid onset of clinical deterioration and early
deaths in this African cohort but it is important to reiterate that appropriate HIV directed
health service interventions such as antiretrovirals, immunoglobulins and prophylaxis against
pneumocystis carinii were not given. The first two were unavailable, and the role of
pneumocystis in these children was unclear at the time of the study. South Africa is a
middle income country and in the midst of an epidemiological transition for childhood
diseases (S A Health Review 1995); therefore there may well be some differences between
the HIV associated disease outcomes described here and those in the rest of Africa.
The onset of disease was early, with infected infants showing signs of disease by one month
of age. The mean age at onset of HIV- related signs and symptoms is within the range of 5-
8 months reported from major studies in the west (Italian Multicentre Study 1988, Scott
1989, Galli 1995). The age at onset is not precisely dated in the African studies, but appears
to be within the first three months of life. In the Rwandan cohort (Lepage 1996) growth
retardation was detected by 3 months of age. In Zaire, significant lymphadenopathy was
detected by 6 months (Jackson 1992).
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By the age of 6 months, 70% of the infected infants in our cohort had signs of disease, and
by 1 year 77% were symptomatic. Similar findings were reported from the Italian group, the
study from Yale, and that from Miami (Italian Multicentre Study 1988, Forsyth 1996, Scott
1989). In the European Collaborative Study, symptoms and signs were most frequent in the
first 18 months of life (ECS 1994). Twenty three percent of the infected children in our
cohort were asymptomatic at one year of age; similar figures were reported from Yale
(Forsyth 1996) and from the Italian study (Italian Multicentre Study 1988) .
The pattern of disease in the Durban cohort was similar to reports from other centres(ECS
1994, ECS 1991, Italian Multicentre Study 1988, Lepage 1990, Forsyth 1996, Galli 1995,
Jackson 1992). Non-specific findings of lymphadenopathy, thrush, failure to thrive and
hepatosplenomegaly occurred early and were the commonest findings in infected infants.
Thrush and pneumonia occurred maximally in the first six months then declined,
lymphadenopathy and hepatosplenomegaly were consistent findings, whilst neurological
abnormalities and diarrhoea gradually increased in frequency. Not unexpectedly, diarrhoea
and pneumonia were frequent problems in the infected infants. However, both conditions
occurred in about half of the uninfected infants as well, and reflect the background problem
of these two conditions in developing countries. Although pneumonia occurred more
frequently in the infected group as a whole (Table 9.2), the number of episodes per child did
not differ significantly between the infected and uninfected (Table 9.3). The aetiologies of
pneumonia and diarrhoea were not documented for this study. Local reports from studies
done subsequently, have shown that the commonest causes of death from severe respiratory
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problems in HIV infected children were pneumocystis carinii and cytomegalovirus (Jeena
1996), and that tuberculosis was uncommon (Jeena 1996). The latter is surprising as the
incidence of tuberculosis is high in South Africa (Dept Health SA 1996). In a separate
study, among children with TB in Durban, 11% were found to be HIV positive. Similar
findings have been reported from Abidjan (Lucas 1996) where pneumocystis was found in
31% of HIV infected children at post-mortem but tuberculosis was low. This issue
requires further investigation of the epidemiology of co-infection but might simply mean
that the sample size in the HIV infected groups was insufficient to detect exposure and
infection by TB.
With regard to diarrhoea, a local study found that infectious diarrhoea in HIV infected
children was due mainly to rotavirus (Rollins N, Wittenberg D, unpublished data). There
was a high frequency of diarrhoea among the uninfected infants, similar to the finding from
a Zairian study (Thea 1993); in addition, the researchers from Zaire noted that the risk for
diarrhoea increased if the HIV positive mother was symptomatic or if she died. This would
likely contribute to the prevalence of diarrhoea in our cohort.
Failure to thrive was a common finding in the infected infants, and occurred significantly
more often than in infants who were HIV exposed but uninfected. Possible reasons for this
include poor nutrition, recurrent diarrhoea and pneumonia, severe oro-pharyngeal thrush.
Having a mother who was too ill to care for the child is another likely explanation; a report
from Haiti showed that infants born to HIV infected women were more likely to be
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malnourished at 3 and 6 months of age (Halsey 1990). In the Nairobi study, it was found
that growth failure occurred more frequently in HIV infected children (Datta 1994);
however a study from Rwanda showed that HIV infected children were more likely to have
stunting but did not have wasting (Lepage 1996). In Europe the figures for failure to thrive
ranged from 14% (ECS 1994, ECS 1991) to 56% (Italian Multicentre Study 1988).
Neurological problems in HIV infected children have been described with varying frequency
in many studies from different parts of the world (Italian Multicentre Study 1988, Forsyth
1996 , ECS 1990, Msellati 1993). In our study, neurological abnormalities occurred in
approximately half of the infected infants and were found as early as 2.3 months of age. In
the Rwandan study, neurological abnormalities were found in 15- 40% overall, with
abnormal signs being detected by 6 months of age (Msellati 1993) Neurological deficits
have been reported far more frequently in USA, i.e. in 60-90% of children, but this figure
occurs in those with established AIDS (Belman 1988). In the European Collaborative
Study, this figure was 8-13% overall (ECS 1990). Surprisingly, there was a high frequency
of neurological problems even in the infants who were exposed but not infected. In a study
from South Africa which looked at responses to acellular pertussis vaccines (Ramkissoon
1991), infants were examined by two pediatricians from birth to 9 months; the prevalence of
neurological problems in this cohort of full term infants was found to be 2.6% (Ramkissoon
1991). The possible reasons for the high prevalence in the uninfected infants are not clear
but may be related to a suboptimal home environment where one or both parents are HIV
infected as has been previously postulated (ECS 1990), or may be due the fact that we did
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not separate the infants into those with developmental problems versus those with tone
disturbances/seizures.
Unlike most studies from the west, a large proportion of infants, 44.4%, developed AIDS in
the first year of life, and a further 2% in the second year. Thereafter, no new case of AIDS
was diagnosed during the study period. In the Italian study, AIDS was present in 23-26% of
infants by the first year of life (Italian Register 1994), and in 40% by 5 years; whilst in the
European Collaborative Study, 23% of infected infants developed AIDS in the first year,
with no child developing AIDS after 20 months of age (ECS 1994, ECS 1991). The rates
of progression to AIDS in Africa are unclear. Researchers from Rwanda have estimated
that the progression to AIDS was 29% in the first 12 months of life and that the median
incubation period was 18.56 months in their study population (Commenges 1992).
One third of the infected infants reported here progressed rapidly downhill, with the
majority of deaths occurring within the first year of life. There were no deaths in the
uninfected group. Mortality in the first year of life was far higher than that found in most
other studies, both in developing and developed countries. In Africa, the frequency of
deaths in the first year ranged from 14% in Kigali (Lepage 1990) to 39% in Brazzaville,
Congo (Lallemont 1989). In Europe and USA this figure ranged from 17%- 25% (ECS
1994, Johnson 1989). The high mortality in our cohort might be attributed to several
factors. At the time of the study, no prophylaxis against, or treatment for, pneumocystis
carinii was used as the prevalence or presence of the organism in the study population was
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not established; and no specific antiretroviral or immunoglobulin therapy was used. In
addition, during this period, there was a great deal of political instability and families were
unsettled.
Three patterns of disease progression have emerged from this study. The first group had
rapidly progressive disease and died within the first year of life; the second group had
slowly progressive disease and were either asymptomatic or mildly symptomatic at the end
of the first year. The third group had rapidly progressive disease in the first 12 months of
life, thereafter they stabilised and remained mildly symptomatic into early infancy and during
the course of the study.
In summary, in this prospective natural history study of vertically acquired HIV-1 infection
in black South African children who were not treated with either antiretrovirals or
immunoglobulin therapy, we have found that signs and symptoms of disease develop early,
progression to AIDS is rapid, and mortality is high in the first year of life. Infected infants
can easily be recognised, even in early infancy, by the profile of HIV-1 associated clinical
problems drawn in this account. This is particularly useful in developing countries, where
diagnostic tests are either not available or are prohibitively costly. In addition, we have
found that about two thirds of infected infants reached early childhood without much
further progression of disease, and that few deaths occurred after the first year of life.
Although we were unable to follow all our infants into late childhood, results from those
who have been followed into early childhood, are similar to the findings of the European
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Collaborative Study (EC S 1994) and the Rwandan study (Lepage 1991) where infected
children beyond five years had few signs and symptoms. This has important health care





GROWTH IN EARLY CHILDHOOD IN A COHORT OF CHILDREN
BORN TO HIV-1 INFECTED WOMEN FROM DURBAN,
SOUTH AFRICA
10.1 Summary
Objectives: to describe growth in a cohort of black South African children with vertically
acquired HIV-1 infection.
Methods: a prospective, hospital-based cohort study. Children born to HIV-1
seropositive women were followed-up from birth to early childhood, at regular intervals.
At birth and each subsequent visit, growth parameters were measured. These children
received no antiretroviral therapy.
Results: there were 48 infected and 93 uninfected children. There were no significant
differences between the two groups at birth; thereafter, the infected group was found to
have early and sustained low mean Z-scores for length-for-age and weight-for-age, but not
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for weight-for-length. Although their means were always lower than those of the
uninfected group, these only reached significance at certain ages: at 3,6, and 12 months
for length, and at 3,6,and 9 months for weight. One third of the infected children had
mean z-scores below -2SD for length at 3 months. Infected children who died early had
more severe stunting, wasting and malnutrition, compared to infected children who
survived.
Conclusions: infected children born to HIV-positive women have early and sustained
linear growth failure, are malnourished, but are not wasted. Children with rapidly
progressive disease have both stunting and wasting and are more severely affected .
Uninfected children of infected mothers are also found to be mildly stunted, but not
generally malnourished or wasted. Early nutritional intervention could be a means of
preventing early progression or death in HIV- infected children, particularly in developing
countries which do not have access to antiretroviral therapy.
10.2 Introduction
Growth in HIV infected children has been described in several studies from developed
countries (ECS 1995,Miller 1993,Moye 1996,Saavedra 1995) and the major impact seems
to be on attainment of normal height. Less information is available on longitudinal growth
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in children from Africa, which has the largest number of HIV-1 infected children. Studies
from Rwanda and Uganda found that HIV infected children had stunting, which began
early, but had no wasting (Lepage 1996, Berhane 1997). Reports from other African
countries have noted marasmus and kwashiorkor in association with HIV infection (Thea
1993). There are many reasons why infected children do not grow well; these include
infections, poor nutrition, and hormonal effects (Thea 1993, Lepage 1991). Recently, a
study from New York reported on an association between viral load and poor growth
(Pollack 1997). This might explain the reported predictive value of malnutrition for
mortality in HIV infected children (Forsyth 1996). Comparisons between HIV infected
children in developed and developing countries are confounded by the availability of anti-
retroviral therapy and adequate prophylaxis in the former.
There are differences in viral subtypes, stage of the epidemic, prevalence of malaria, socio-
economic class, and availability of health services between central and east Africa and
South Africa. These might affect growth of children.
We report on growth in the first 18 months of life in a cohort of children born to HIV-
infected black women from Durban, South Africa, during the early stage of the epidemic.
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10.3 Patients and Methods
Refer Chapter 3 for details.
10.3.1 Mothers and infants
The sampling method has been previously described in detail in Chapter 3.
10.3.2 Classification
Refer Chapter 3 for details.
10.3.2 Definitions
The anthropometric data was defined according to previously recommended terms .
Children were classified as being wasted, stunted, or malnourished, depending on the
weight-for-length, the length -for-age, or the weight-for-age (NCHS 1976) .
10.3.3 Laboratory methods
Refer Chapter 3 .
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10.3.4 Statistical methods
Anthropometric indices, weight for age, length for age, and weight for length, were
calculated using the growth reference curves developed by the National Centre for Health
Statistics and CDC, as recommended by the WHO (WHO 1986, Dibley 1987). For each
of these indices, the Z-score was estimated. The Z-score for weight for age, for example,
is calculated by subtracting the median weight of the reference population at the child's
age from the child's weight and dividing by the standard deviation of the weight of the
reference population at that age. The Z-score results are reported as means and standard
deviations at each age. HIV infected and uninfected infants were compared with relation
to the mean Z-score using Student's unpaired t-test. The percentage of low
anthropometric indices, using a cut-off value of < -2SD, was calculated and compared
between infected and uninfected infants using a Chi-square test.
10.4 Results
Refer Chapter 3 for general results.
The mean follow up period for the infected infants was 28.5 months, and for the
uninfected infants was 23.6 months.
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10.4.1 Classification
The children were classified as 48 infected (including 17 deaths); 93 not infected, and 40
indeterminate (including 8 deaths). The 17 infected children who died during the first two
years of life were regarded as rapid progressors; mean age at death was 10.1 months
(range 1-48 months). All the children who died were receiving either predominant
breastfeeds or mixed feeds (breast and formula).
10.4.2 Growth
Length for age: at birth, there were no significant differences between the infected and
uninfected groups, and they compared well to international standards. Thereafter, the
mean z-scores for length in the infected children fell below the international standards, and
remained below those for the uninfected group (Table10.1 and Figure 10.1). There was a
significant difference in the length-for-age between the infected and uninfected children at
the ages of three, six and 18 months. Stunting also occurred in the uninfected group from
the age of three months; however, the means were always above those of the infected
group. The proportion of infected children with length-for-age z-scores below -2SD were
27% at 3 months, 42% at 15 months, and 45% at 18 months.
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Table 10.1 Mean weight-for-age, length-for-age, and weight-for-length z-scores
in 111V-1 infected and uninfected children, born to seropositive
mothers
Age Infected Uninfected p value
(months) Mean (SD)* Mean (SD)
Weight:
Birth 0.101 (0.61) 0.397 (1.12) 0.379
3 -0.688 (1.21) 0.696 (1.57) 0.002
6 -0.611 (1.51) 0.412 (1.30) 0.006
9 -0.747 (1.48) 0.180 (1.40) 0.042
12 -0.529 (1.43) -0.364 (1.53) 0.709
15 -1.031 (1.96) -0.378 (1.42) 0.178
18 -0.899 (1.14) -0.032 (1.43) 0.073
Length:
Birth 0.132 (0.73) 0.239 (1.01) 0.574
3 -1.365 (1.74) -0.200 (1.53) 0.014
6 -1.143 (1.38) -0.079 (1.40) 0.006
9 -0.773 (1.01) -0.733 (1.16) 0.913
12 -1.262 (1.50) -1.005 (1.36) 0.526
15 -1.828 (1.58) -1.098 (1.24) 0.079




3 -0.431 (0.680) -0.239 (1.01) 0.552
6 0.419 (1.10) 0.935 (1.25) 0.152
9 0.337 (1.56) 0.558 (1.43) 0.578
12 -0.202 (1.59) 0.997 (1.51) 0.015
15 0.498 (1.04) 0.535 (1.56) 0.931
18 0.133 (0.41) 0.456 (1.45) 0.514




Figure 10.1 Mean length for age z-scores
Age in months
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Weight-for-age: at birth, the two groups compared well to international standards.
Thereafter, the means for the infected group fell, and remained below those of the
uninfected group (Table 10.1 and Figure 10.2). The differences were significant at ages 3,
6, and 9 months. Of note, in the uninfected group, weights were unaffected initially, but
the means dropped after the age of 9 months.
Weight-for-length: at birth, the means for both the infected and uninfected group were
low, thereafter, they remained comparable to international means, except at 9 months,
when the means for the infected group were significantly lower than those of the
uninfected group (Table 10.1 and Figure 10.3).
Growth parameters in the rapid progessors: we compared growth parameters between the
17 infected children who died with the 31 infected children who survived (Table 10.2).
Although the numbers were small, a definite trend was noted. Differences in weight and
length, which were noticeable from birth, persisted throughout in those infants who died .
They had more severe stunting and malnutrition, and also had wasting. Seven of the 17
who died (42%), had length-for-age mean z-scores below -2SD.
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Figure 10.3 Mean weight for length z-scores
Age in months
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Table 10.2 Mean weight-for-age, length-for-age, and weight-for-length z-scores
in HIV-1 infected children, comparing those who died with those who
survived
Age# Infected, Died Uninfected, Alive
(months) Mean (SD)* Mean (SD)
n=17 n=31
Weight:
3 -1.508 (0.79) -0.278 (1.21)
6 -2.597 (1.10) -0.043 (1.07)
9 -2.035 (1.04) -0.489 (1.46)
15 -3.585 (0.33) -0.520 (1.71)
Length -
3 -2.086 1.95 -1.005 1.60
6 -1.917 2.17 -0.922 1.07
9 -0.900 1.05 -0.747 1.06
15 -3.320 0.48 -1.530 1.55
Weight
for length:
3 0.084 1.39 0.587 0.97
6 -1.465 0.89 0.852 1.35
9 -1.685 0.47 0.095 1.58
15 -2.080 0.04 0.575 1.12
*SD=standard deviation




In this prospective cohort study on children born to 111V-1 infected black women, we have
found that children with vertically transmitted infection showed early onset of stunting,
were generally undernourished, but did not have significant wasting. However, infected
children with rapidly progressive disease had both wasting and stunting, with the
differences in weight and length being present from birth. The uninfected group had mild
stunting and malnutrition, which occurred later in infancy; but they had no wasting. This
pattern was similar to that found in a population of black children, from Durban, prior to
the HIV epidemic (Coovadia 1978).
Our results confirm and extend data from other studies. Other African studies, from
Rwanda and Uganda, found that children with vertically acquired HIV-1 infection were
frequently undernourished, were stunted, but not wasted (Lepage 1996, Berhane 1997).
Similar results have been shown in New York, where infected children were found to have
early and frequent stunting (Pollack 1997). Our cohort of children, like those from
Rwanda, received no antiretroviral therapy, and are comparable, whereas in the New York
study, 61% of infected children received antiretroviral drugs. In addition, the study from
Uganda noted an increase in mortality in association with the severity of growth failure
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(Berhane 1997). Similarly, in our cohort, children who died had more severe wasting and
stunting.
It is not clear why HIV-infected children have growth failure. The study from New York
has suggested that an increased viral load is a probable contributing factor (Pollack 1997).
Children in their cohort had disturbed linear growth which corresponded to higher viral
loads. They did not find a difference in growth related to the use of antiretroviral agents.
Although we did not measure viral load, it is likely that this might have been associated
with the growth disturbances we detected. Differences in length and weight in the HIV-
infected group were present from birth (although not significant), but were profound by
the third month of life. This parallels findings from recent studies on viral dynamics in
which it has been established that the RNA viral burden peaks between 3 to 4 months of
age from a relatively lower value at birth. The fact that HIV uninfected children also had a
similar progression of stunting suggests that environmental conditions prevailing within
families and communities are responsible. These factors have been discussed in a recent
review on protein energy malnutrition in South African children (Glatthaar 1994).
In the cohort from Rwanda , an association was noted between growth failure and
infections (Lepage 1996). Infected children with low weight and length for age were more
likely to have had persistent diarrhoea, chronic fever and pneumonia. In a previous
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description of our cohort, we have shown that the commonest causes for mortality in HIV
infected children were either respiratory, diarrhoeal, or both. In addition, we showed a
high proportion of failure to thrive (Bobat 1998). Persistent or recurrent diarrhoea and
malabsorption have been associated with growth failure in HIV infected children (DuPont
1995). However, we did not find a significant difference in frequency of diarrhoea and
respiratory infections between those infected children who were the most severely
stunted, i.e. those who fell below -2SD for length, compared to the rest of the infected
group.
Malnutrition has been shown to affect immunity (Gorbach 1993) and this predisposes to
opportunistic infections. An association between growth failure and opportunistic
infections has been shown in haemophiliac children (Bretler 1990). The combination of
malnutrition and opportunistic infections would aggravate the problem of growth failure in
HIV infected children.
There have been reports that endocrine dysfunction may be associated with the growth
failure occurring in HIV infected children (Lepage 1991). Thyroid and adrenal
abnormalities have been documented in HIV infection (Membreno 1997). What the exact
role of these in HIV related growth failure is, remains uncertain. In South Africa,
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endocrine dysfunction has been described in relation to malnutrition (Wittenberg 1998),
and this may be one of the mechanisms for the growth failure.
The finding of growth failure in the children who were uninfected is interesting. It may be
related to the problem of having an HIV- infected mother who is ill. as has been previously
suggested (Halsey 1990); or be the consequence of dysfunctional families, or may be
associated with the background poverty prevalent in South Africa. Figures from a
randomised national sample of children in South Africa showed that the prevalence of
underweight children was 9.3%, and that stunting occurred in 23% of children (SAVCG
1996).
We do not have an adequate explanation for the profound effect on stunting compared to
the lack of significant wasting, found in our study, as well as in other African studies.
Stunting probably reflects more than simple intake of food, and is likely a result of the
combination of poor overall economic conditions, chronic or repeated infections, as well
as inadequate nutrient intake (Dibley 1987). In addition, in the presence of HIV infection,
it may be related to viral load (Pollack 1997); it has been shown that children who receive
antiretroviral therapy grow better (McKinney 1991).
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Growth failure in an infant born to an HIV-infected woman may be an indicator of
infection in the child, or an indicator of rapidly progressive disease in an infected child, and
should alert the physician to the need for possible intervention. Infected children with
severe wasting and stunting are at particular risk for early death, and need to be monitored
closely. The cause of growth failure in these children may be a combination of lack of
food, frequent infections, and higher viral load. In most developing countries, where
antiretroviral therapy is unavailable, early nutritional support may be an important




MORTALITY IN CHILDREN BORN TO HIV-1 INFECTED WOMEN
11.1 Summary
Ojectives: to describe mortality in a cohort of infants with vertically transmitted HIV-I
infection .
Patients and Methods: children of HIV-1 infected women were followed up from birth and
record made at each visit of growth, development, and all illnesses. Details surrounding death
were obtained from hospital records.
Results: the final cohort comprised 48 infected and 93 uninfected children; there were 25
deaths, of which 17 (3 5%) were regarded as HIV-related. The mean age at death of HIV-
related cases was 10.1 months (range 1-48 months), and eighty three percent of HIV-related
deaths occurred before the age of 10 months. The commonest diagnoses at the time of death
were diarrhoea, pneumonia, failure to thrive and severe thrush. These findings, together with
neurological abnormalities, often presaged rapid deterioration and death
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Conclusions: mortality among children with vertically acquired HIV infection is high in the
first year of life. Death in these subjects was due to the common causes of morbidity and
mortality among all children in developing countries. The combination of findings of diarrhoea,
pneumonia, failure to thrive, and neurological abnormalities, should alert one to the possibility
of rapidly progressive disease and death.
11.2 Introduction
Children with vertically acquired HIV-1 infection appear to progress at different rates to severe
disease and death (Forsyth 1996). Whilst some, about 23-26%, have a rapidly progressive
course with death within the first year, others follow a less turbulent path and remain well into
late childhood (Scarlatti 1996). With the use of antiretroviral drugs, prophylaxis against
pneumocystis carinii and other infections in developed countries, and with better nutritional and
anti-infective measures during care, children are now surviving longer and in a better general
state of health. In Africa, which bears the brunt of the disease, these interventions are generally
not available, because of lack of resources. Knowledge of the patterns and causes of death in
HIV-infected children would enable the development of suitable management programmes
targeted at these diseases. In addition, the possibility of prognostication and identification of
REV-infected children who will progress to early death would be possible. Some information
is available on the causes of death in HIV-infected children from Africa (Taha 1995, Hira
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1989, Vetter 1996) but these data are limited for a number of reasons including low autopsy
rates in general and a particular reluctance to undertake postmortems in HIV infected
individuals.
We present the causes of these early deaths in a cohort of children followed from birth.
11.3 Methods
Details on methods and patient population have been described in Chapter 3.
Most deaths occurred either in the study hospital's outpatient department or in the paediatric
wards, and information for these children was obtained from the hospital records. Sufficient
data on the deaths was not possible for all the patients , since some died at home, and the only
available information was that obtained from the mother subsequent to the child's death. These
children were classified as indeterminate as the actual cause of death and the relationship to
HIV could not be established.
Postmortems were not conducted if the child was known to be REV-positive, as this was the
policy of the Pathology department at the study hospital.
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11.4 Results
The final cohort comprised 48 infected and 93 uninfected children. There was a total of 25
known deaths in the entire cohort during the study period. Of these, 17 deaths were classified
as HIV-related, and 8 as indeterminate. In the REV-related group, the mean age at death was
10.1 months (range 1 month to 48 months). Only 3 deaths occurred after 12 months of age.
If the 3 late deaths are excluded, then the mean age at death in the first 12 months was 3.8
months. Eighty three percent of all deaths occurred before 10 months of age.
11.4.1 Symptoms and clinical features at death:
The onset of symptoms in the infants who died was at a mean age of 3 months, (range 1 to 5
months). The main presenting complaints or symptoms just prior to death were cough,
diarrhoea, and fever (Table 11.1); at least two of these symptoms were found in 16/17 of the
infants who died from an HIV-related death. The main morbidity data are summarised in
Table 11.2.
11.4.2 Laboratory data at death:
Of the 7 children for whom full blood counts were available, 5 (71.4%) had anaemia of varying
degrees; thrombocytopaenia and leucopaenia were found in one child only. This infant had
pancytopaenia. The mean globulin level was 35.7 (range 21-74 g/1 ). Positive blood cultures
were obtained in 4 children, of which 3 were gram negative organisms (Table 11.3).
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Table 11.1. Presenting complaints and clinical features at death for each HIV-1















8 y y Y y y
72 fever,cough,
tachypnoea




1 n y Y y n n
94 fever, cough
diarrhoea
2 y y Y n n y
104 diarrhoea 24 y y Y y n y
105 diarrhoea 24 y y N y y y
106 fever,cough
diarrhoea
2.5 n y Y Y y n
111 fever,cough
diarrhoea
3 y y Y y y y
l25 fever,cough
diarrhoea
31 n y Y y y y
138 fever, diarrhoea 5.5 y y Y y y y
153 excessive crying 2.5 y n N n n y
177 fever, diarrhoea 3.5 y y Y y y n
179 fever, cough
diarrhoea
6 y y N y n n
181 cough, diarrhoea 9 y n Y y y y
198 fever, cough 2.5 y n Y n n n
203 fever, cough,
diarrhoea
5.5 y y N y y Y
220 fever, diarrhoea 1.5 n y Y y n N
# pneumonia * diarrhoea (ID neurological abnormalities
4. lymphadenopathy y=yes n=not present
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diarrhoea 13 76.5 56.3 - 96.3
severe thrush 13 76.5 56.3 - 96.6
failure to thrive/
marasmus
12 70.6 48.9 - 92.2
pneumonia 12 70.6 48.9 - 92.2
significant
lymphadenopathy
10 58.8 35.4 - 82.2
neurological abnormality/
delayed development
9 52.9 29.2 - 76.7
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blood culture chest x-ray Other
18 n/a 67 no growth bi-lateral
extensive
pneumonia
72 12.6 11.9 290 n/a no growth bilateral
broncho-
pneumonia
pm # lung biopsy:
pneumonia
79 n/a 29 pseudomonas right broncho-
pneumonia
94 n/a 22 no growth n/a
106 n/a 21 no growth clear















177 6.6 4.3 45 21 enterococcus bi-lateral
pneumonia
179 10.4 8.3 317 27 n/a n/a
181
n/a
no growth n/a CMV IgM positive




* information was not available for every patient who died
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11.5 Discussion
The mortality for the infected children in this cohort, during the period of follow-up, was
35.4%, with the majority of the HIV-related deaths occurring before the age of one year. It is
clear from the complaints, symptoms, and clinical findings, that most deaths were related to
either diarrhoeal disease or respiratory infection, or both, 12/17 (70.5%). The majority of the
infants had failure to thrive or marasmus at the time of death, and half of them had neurological
signs and/or developmental delay. HIV-related disease developed early and was rapidly
progressive in these children, with mortality being the highest in the first year of life.
These children had illnesses similar to most children in developing countries, and therefore
diarrhoeal disease and respiratory infections, per se, cannot identify the HIV-infected child who
will develop rapidly progressive disease. However, most of these infants also had failure to
thrive, and a high proportion had neurological abnormalities. In an analysis on the newborn
infants in this cohort, it was noted that those HIV positive infants who died early had lower
birth weights, and were more likely to have complications in the newborn period.
It would be the combination of features: diarhoeal disease, respiratory infection, failure to
thrive, and neurological abnormalities, as well as the findings of low birth weight and neonatal
complications in the newborn of an HIV-positive mother, that would alert one to the child who
is HIV-infected and who would develop rapidly progressive disease and early death.
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These findings are similar to those reported from central Africa. In the report from Malawi,
diarrhoeal disease, respiratory infections and failure to thrive were the commonest cause of
death and mortality in the first year was high (Taha 1995). Similarly, in Lusaka, Zambia, it
was found that mortality among vertically infected children was 44 % at 2 years, and the main
clinical findings included pneumonia, diarrhoea, failure to thrive, and fever (Hira 1989). A
study from Kinshasa reported a 3-year mortality of 44 % in children born to HIV-1 infected
women, with diarrhoea and pneumonia being among the chief causes of death (Ryder 1994).
The proposed new Integrated Management of Childhood Infections initiative incorporates the
management of the major causes of illness and death in African children, i.e. diarrhoea,
pneumonia, measles, malaria and malnutrition (IMCI 1997). The shortcoming of this
protocol is that HIV infection has not been included among these. Our data highlights the
role of diarrhoeal disease, respiratory infections, and malnutrition in HIV- related mortality
and, given the extent of the epidemic in Africa, and the increase in childhood mortality from
HIV (Nicoll 1995), it would be crucial to include the role of HIV in any management
protocol dealing with childhood infections in Africa. In particular attention must be given to
the problems of repeated and often protracted diarrhoea, recurrent or chronic pneumonia, as
well as a high frequency of failure to thrive in children with vertically acquired HIV
infection.
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In conclusion, mortality among children with vertically acquired HIV-1 infection is high in
the first year, and the pattern of illnesses are similar to those reported in other parts of Africa.
The combination of findings in HIV infected children of diarrhoea, pneumonia, failure to
thrive, and neurological abnormalities, should alert one to the possibility of rapidly
progressive HIV disease and early death. In addition, it highlights the need for early and
aggressive management of these infections in HIV-infected children, and the need for early





This natural history study, conducted during the early phase of the epidemic in
KwaZulufNatal, has revealed some important observations which are important in the
counselling of HIV positive expectant and new mothers; in the early recognition of infected
infants; in the planning of appropriate management of infected children; and in the
counselling of mothers with infected children.
This study has shown that the vertical transmission rate was high, 34%, and that that there
was an increased rate of transmission associated with vaginal deliveries and anaemia in
pregnancy.
There was an increased risk of transmission, by about 15%, associated with breastfeeding.
Exclusive breastfeeding by HIV-infected mothers did not appear to protect their infants against
common childhood illnesses and failure to thrive, nor significantly delay progression to AIDS;
and there was a trend towards higher mortality in those receiving exclusive breastfeeds.
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As a group, vertically infected newborns of HIV-positive mothers could not be differentiated
from those who were exposed, but uninfected. However, infected newborns of HIV-positive
women who were found to be growth retarded, or who developed complications in the
neonatal period, were more likely to progress rapidly and die. Such infants probably
represented intrauterine or early intra-partum transmission.
In children with vertically acquired HIV-1 infection, the onset of disease was early and
deterioration to AIDS and death were rapid. Infected infants could be easily recognised
clinically, the majority by 6 months of age, which is particularly useful in developing countries.
Two thirds of infected infants survived beyond infancy; this has important implications for
management and health care planning.
Infected children born to HIV-positive women had early and sustained linear growth failure,
malnutrition, but not wasting. This possibly reflects a combination of the effects of the disease
and environmental factors, and has important implications for early nutritional interventions.
Mortality among children with vertically acquired HIV infection was high in the first year of
life. Death in these subjects was due to the common causes of morbidity and mortality among
all children in developing countries. The combination of findings of diarrhoea, pneumonia,
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failure to thrive, and neurological abnormalities, should alert one to the possibility of rapidly
progressive disease and death.
Three patterns of disease have emerged from this study:
• rapidly progressive disease and early death
• initial rapid progression, followed by stabilisation
• slowly progressive disease
The results from this study provide health care workers in developing countries with additional
information with regard to the factors contributing to vertical transmission and the effects of
breastfeeding on vertical transmission and on morbidity. It provides the natural history of
vertically transmitted HIV-1 infection during a period when no intervention was available; it
provides clinical manifestations of the disease progress and the effects on growth. The study
also provides information on the causes of mortality in vertically infected children. All this
information contributes to improved care/management of HIV infected children, and provides
direction for future research.
Much information is still required on the timing of vertical transmission and the effects of
truly exclusive breastfeeding; the effect on vertical transmission of interventions such as the
use of antiretroviral drugs and no breastfeeding. Future studies need to investigate, in depth,
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Table 1: National HIV surveys of women attending antenatal clinics of the public health
services in South Africa, 1994 - 1996
1996
Est (HIV+) 95% CI
1995
Est (HIV+) 95% CI
1994
Est (HIV+) 95% CI
South Africa 14,17 (13,45 ; 14,89) 10,44 ( 9,86 ; 11,02) 7,57 ( 7,01 ; 8,12)
Provinces
Western Cape 3,09 ( 2,34 ; 3,84) 1,66 ( 0,94 ; 2,38) 1,16 ( 0,76 ; 1,56)
Eastern Cape 8,10 ( 6,92 ; 9,28) 6,00 ( 4,89 ; 7,11) 4,52 ( 3,85 ; 5,19)
Northern Cape 6,47 ( 5,05 ; 7,89) 5,34 ( 4,10 ; 6.58) 1,81 ( 1,09 ; 2,53)
Free State 17,49 (15,57 ; 19,41) 11,03 ( 9,44 ; 12,62) 9,19 ( 7,94 ; 10,44)
KwaZulu-Natal 19,90 (17,68 ; 22,12) 18,23 (16,31 ; 20,15) 14,35 (12,22 ; 16,48)
Mpumalanga 15.77 (14,34 ; 17,20) 16,18 (14,40 ; 17,96) 12,16 (11,60 ; 12,71)
Northern Province 7,96 ( 6,24 : 9.68) 4,89 ( 4,00 ; 5,78) 3.04 ( 2,40 ; 3 .6 7 )
Gauteng 15,49 (13,58 ; 17,40) 12.03 (10,36 , 13.70) 6,44 ( 5,63 ; 7,25)
North West 25.13 (22,31 ; 27,95) 8.30 ( 6,67 ; 9,92) 6,71 ( 4,62 ; 8,80)
Age Group
<20 12,90 (11,45 : 14,35) 9.50 ( 8,15 ; 10,85) 6,47 ( 5,45 ; 7,49)
20 - 24 17,74 (16,49 ; 18,99) 13,12 (11,97 ; 14,27) 8,94 ( 8,02 ; 9,86)
25 - 29 15,33 (14,04 ; 16,60) 11,03 ( 9,81 ; 12.25) 8,63 ( 7,25 ; 10,01)
30 - 34 12,20 (10,73 ; 13,67) 8,05 ( 6,79 ; 9.31) 6,37 ( 5,28 ; 7,45)
35 - 39 9,71 ( 7,89 ; 11,53) 7,37 ( 5,47 ; 9,28) 3,72 ( 2,34 ; 5,11)
40 - 44 10,16 ( 5,95 ; 14.36) 4,36 ( 1,96 ; 6,76) 5,28 ( 3,21 ; 7,35)
45 - 49 * 5,83 ( 2,24 , 9,40) 7,45 ( 0,00; 19,36) 0,41 ( 0,00 ; 1,16)
Note:The estimate of HIV prevalence in the 45 - 49 year group is based on very small numbers.





WHO/UNICEF STATEMENT ON BREAST-FEEDING
Recommendations
1. In all populations, irrespective of HIV rates, breast-feeding should continue to be protected,
promoted and supported.
2. Where the primary causes of infant deaths are infectious diseases and malnutrition, infants
who are not breast-fed run a particularly high risk of dying from these conditions. In these
settings, breast-feeding should remain the standard advice to pregnant women, including
those who are known to be HIV-infected, because their baby's risk of becoming infected
through breast milk is likely to be lower than its risk of dying of other causes if deprived of
breast-feeding.
3. In settings where infectious diseases are not the primary causes of death during infancy,
pregnant women known to be infected with HIV should be advised not to breast-feed but to
use a safe feeding alternative for their babies.
195
4. When a baby is to be artifically fed, the choice of substitute feeding method and product
should not be influenced by commercial pressures. Companies are called on to respect this
principle in keeping with the International Code of Marketing of Breast-milk Substitutes.
5. In all countries, the first and overriding priority in preventing HIV transmission from
mother to infant is to prevent women of childbearing age from becoming infected with HIV
in the first place.
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Annexure
UNAIDS STATEMENT ON BREAST-FEEDING
Support breast-feeding
As a general principle, in all population, irrespective of HIV infection rates, breast-
feeding should continue to be protected, promoted and supported .
Improving access to HIV counselling and testing
Access to voluntary and confidential HIV counselling and testing should be facilitated
for women and men of reproductive age. Counselling for women who are aware of
their HIV status should include the best available information on the benefits of breast-
feeding, on the risk of HIV transmission through breast-feeding, and on the risks and
possible advantages associated with other methods of infant.
3. Ensuring informed choice
Because both parents have a responsibility for the health welfare of their children, and
because the infant feeding method chosen has health and financial implications for the
entire family, mothers and fathers should be encouraged to reach a decision together on
this matter. Women be empowered to make fully informed decisions about infant
feeding, and that they be suitably supported in carrying them out.  This should include
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efforts to promote a hygienic environment, essentially clean water and sanitation, that
will minimize health risks when a breast-milk substitute is used.
When children born to women living with HIV can be ensured uninterrupted
access to nutritionally adequate breast-milk substitutes that are safely prepared and
fed to them, they are at less risk of illness and death if they are not breast-fed .
However, when these conditions are not fulfilled, in particular in an environment
where infectious diseases and malnutrition are the primary causes of death during
infancy, artificial feeding substantially increases children's risk of illness and death .
4. Preventing commercial pressures for artificial feeding
Manufacturers and distributors of products which fall within the scope of the
International Code of Marketing of Breast-milk Substitutes (1981) should be
reminded of their responsibilities under the Code and continue to take the
necessary action to ensure that their conduct at every level conforms to the
principles and aim of the Code.
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Annexure IV
Categories for CDC Classification of HIV Infection
Category N : Not Symptomatic
Children who have no signs or symptoms considered to be the result of HIV infection or who
have only one of the conditions listed in Category A.
Category A : Mildly Symptomatic
Children with two or more of the conditions listed below but none of the conditions listed in
categories B and C.





• Recurrent or persistent upper respiratory infection, sinusitis, or otitis media
Category B : Moderately Symptomatic
Children who have symptomatic conditions other than listed for Category A or C that are
attributed to HIV infection. Examples of conditions in clinical Category B include but are not
limited to
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• Anaemia (<8 g/dL), neutropenia (<1000/mm 3), or thrombocytopenia (<100,000/mm 3 )
persisting _̂30 days
• Bacterial meningitis, pneumonia, or sepsis (single episode)
• Candidiasis, oropharyngeal (thrush), persisting (>2 months) in children >6 months of age
• Cardiomyopathy
• Cytomegalovirus infection, with onset before 1 month of age
• Diarrhoea, recurrent or chronic
• Hepatitis
• Herpes simplex virus (HSV) stomatitis, recurrent (move than two episodes within 1 year)
• HSV bronchitis, pneumonitis, or esophagitis with onset before 1 month of age
• Herpes zoster (shingles) involving at least two distinct episodes or more than one
dermatome
• Leiomyosarcoma
• Lymphoid interstitial pneumonia (LIP) or pulmonay lypmhoid hyperplasia complex
• Nephropathy
• Nocardiosis
• Persistent fever (lasting >1 month)
• Toxoplasmosis, onset before 1 month of age
• Varicella, disseminated (complicated chickenpox)
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Category C: Severely Symptomatic
• Serious bacterial infections, multiple or recurrent (i.e., any combination of at least two
culture-confirmed infections within a 2-year period), of the following types: septicemia,
pneumonia, meningitis, bone or joint infection, or abscess of an internal organ or body
cavity (excluding otitis media, superficial skin or mucosal abscesses, and indwelling
catheter-related infections)
• Candidiasis, oesophageal or pulmonary (bronchi, trachea, lun gs)
• Coccidioidomycosis, disseminated (at site other than or in addition to lungs or cervical or
hilar lymph nodes)
• Cryptococcosis, extrapulmonary
• Cryptosporidiosis or isosporiasis with diarrhoea persisting >1 month
• Cytomegalovirus disease with onset of symptoms at ge >1 month (at a site other than liver,
spleen or lymph nodes)
• Encephalopathy (at least one of the following progressive findings present for at least 2
months in the absence of a concurrent illness other than HIV infection that could explain
the findings): a) failure to attain or loss of developmental milestone or loss of intellectual
ability, verified by standard developmental scale of neurosychological tests; b) impaired
brain growth or acquired microcephaly demonstrated by head circumference measurements
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or brain atrophy demonstrated by CT scans or MR imaging (serial imaging is required for
children < 2 years of age); c) acquired symmetric motor deficit manifested by two or more of
the following: paresis, pathologic reflexes, ataxia, or gait disturbance
• Herpes simplex virus infection causing a mucocutaneous ulcer that persists for >1 month; or
bronchitis, pneumonitis, or oesophagitis for any duration affecting a child >1 month of age
• Histoplasmosis, disseminated (at a site other than or in addition to lungs or cervical or hilar
lymph nodes)
• Kaposi's sarcoma
• Lymphoma, primary, in brain
• Lymphoma, small, noncleaved cell (Burkitts), or immunoblastic or large cell lymphoma of
B-cell or unknown immunologic phenotype
• Mycobacterium tuberculosis, disseminated or extrapulmonary
• Mycobacterium, other species or unidentified species, disseminated (at a site other than or
in addition to lungs, skin or cervical or hilar lymph nodes)
• Mycobacterium avium-intracellulare complex or Mycobacterium kansasii, disseminated (at
site other than or in addition to lungs, skin, or cervical or hilar lymph nodes)
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• Pneumocystis carinii pneumonia
• Progressive multifocal leukoencephalopathy
• Salmonella (nontyphoid) septicemia, recurrent
Immune Categories:
Age of Child
Immune Category </=12 months 1 — 5 years 6 — 12 years
Number/ ul/ % Number/ a `)/0 Number/ ul/ %
Category 1:
No suppression
>/=1,500/> 25% >/=1,000/ >25% >/=500/ >25%
Category 2:
Moderate suppression
750-1,499/15-24% 500-999/ 15-24% 200-499/ 15-24%
Category 3: Severe
suppression
<750/ < 15% <500/ < 15% <200/ < 15%
